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ABSTRACT 
The Thesis entitled "Kinetics and Mechanism of Oxidation of Organic 
Compounds" deals with oxidative degradation of few selected drugs i.e. Paracetamol 
and Diclofenac sodium by potassium permanganate and potassium dichromate as an 
oxidant under pseudo-first order conditions with an aim to determine various kinetic 
parameters i.e. Specific rate constant, order of reaction with respect to each reactants, 
over all order of the reaction, rate expression and activation parameters of the 
reactions. An attempt has also been made to suggest the possible structure of the 
different products formed during the course of oxidation reactions process through 
UV-visible spectral analysis technique in order to have a better understanding of the 
mechanism involved in these processes. This thesis is divided into four chapters. 
The Chapter 1 deals with "Introduction-An Overview on the Characteristics, 
Environmental Relevance and Degradation of Paracetamol and Diclofenac sodium". 
This chapter completely describes an introduction giving an overview on (i) The 
characteristics of these drugs, (ii) Their environmental relevance, (iii) Results 
published in literature on their degradation and (iv) Research work carried on these 
drugs by various research groups. 
The Chapter 2 deals with "Oxidative Degradation of Paracetamol by Permanganate 
in neutral medium-A Kinetic and Mechanistic Pathway" to study the kinetic 
parameters under pseudo-first order conditions to obtain reaction order with respect to 
each reactant using first-order integrated rate equation. 
log([A]o/[A]) = kt/2.303 
The spectrophotometric kinetic studies were performed on the basis of the absorbance 
(optical density) noted at >.niax (wavelength) as a function of time. These reading were 
conveniently made with a Genesis 20 spectrophotometer for relatively slow reactions. 
The sample was withdrawn from the thermostated reaction mixture for measurement. 
The progress of the oxidative degradation was also followed by UV-visible 
spectroscopy. The reaction rate increases with [Paracetamol] in the range of 1.81 xlO''' 
to 4.28xlO'^'min''.The structural characterization was studied by UV-visible 
spectroscopy. The spectral change (characteristic peaks) in the course of reaction was 
observed in the region 400 nm to 525 nm and there was a gradual decrease in 
absorption intensity at its A,max (525 nm).The kinetic data for the oxidation of 
paracetamol indicates the order with respect to each reactants, i.e.; both [Paracetamol] 
and [Mn04"] is one. The slope of log k versus 1/T also confirms the first order 
dependence on the reactant. The activation parameters such as Ea, AH'', AS* and AG" 
were also evaluated for the reaction and found to be 23.9 kJ.mol" , 21.4 kJ.mol' , -225 
J.K"' mof' and 88.4 kJ.mol"', respectively. Probable mechanism with the observed 
kinetic results has been suggested. 
Chapter 3 "Kinetics and Mechanism of Oxidative Degradation of Paracetamol by 
Potassiuum dichromate in Acidic Medium". The study deals with the kinetics of 
oxidative degradation of paracetamol by dichromate in acidic medium was studied 
spectrophotometrically, hi.d to evaluate the kinetic parameters under pseudo-first 
order conditions. The reaction-order with respect to each reactant using first-order 
integrated rate equation is given in chapter 2. The degradation process was slow with 
pseudo-first order rate constant 26.3x10'^ min"' to 08.4x10'^ min'' at various 
concentration of dichromate. The rate increased with an increase in the concentration 
of both of the reactants. The kinetic data for the oxidation of paracetamol indicates the 
order with respect to each reactant, i.e.; both [Paracetamol] and [Dichromate] is one. 
The course of degradation was studied by UV-visible spectroscopy. The spectral 
change in the course of reaction, the absorption intensity in the region 345-350 nm 
decreased gradually as the reaction proceeded. Increasing reaction temperature and 
oxidant concentration can accelerate the paracetamol degradadon rates. The activation 
energy with respect to slow step of the mechanism is calculated and discussed (Ea = 
14.1 kJ.mof'). 
Thermodynamic quantities AH*, AS", and AG* are computed by using Eyring equation 
and found to be 11.5 kJ.mol"', -242 JK"'.mor' and 85.9 kJ.mol"', respectively. A 
probable mechanism for the reaction has been suggested. 
Chapter 4 "Oxidative Degradation of Diclofenac sodium by Permanganate in 
neutral medium-A Kinetic and Mechanistic Pathway" deals with the kinetics of 
oxidation of Diclofenac sodium with potassium permanganate in neutral medium 
under pseudo-first order conditions to obtain the different kinetic parameters of the 
reaction. The reaction follows truly first-order kinefics with respect to each reactant. 
The course of degradation was studied by UV-visible spectroscopy. The spectral 
change in the course of reaction was studied in the range 450-750 nm, As expected, 
the absorption intensity in the region 510-600 nm (characteristic peak complex for 
permanganate) decreased gradually as the reaction proceeded. Increasing reaction 
temperature and oxidant concentration can accelerate the Diclofenac sodium 
degradation rates. The effect of temperature on reaction rate is discuss with the help 
of Arrhenius equation i.e. k = ze-^ .^ This equation also helps to calculate the 
activation energy of the reaction and it was found to be 21.1 kJ.mol"'. 
The plot of log k versus 1/T of the reaction give straight line with negative slope that 
confirm that reaction follows first-order kinetics with respect to each of the reactant. 
Thermodynamic quantities AH , AS* , and AG*' are computed by using Eyring 
equation and found to be 18.5 kJ.mol'', -236 JK''.mor' and 88.9 kJ.mol'', 
respectively. Thus, finally the rate expression is deduced for the reaction under study. 
Other oxidants like potassium dichromate, ammonium molybedate were also used 
with Diclofenac sodium in acidic as well as in neutral medium but they did not show 
degradation behavior. 
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CHAPTER! 
Introduction-An Overview on the 
Characteristics, Environmental Relevance 
and Degradation of Paracetamol and 
Diclofenac Sodium 
Environmental pollution has become an important issue for the society. 
Virtually any human activity leads to an environmental contamination with substances 
of anthropogenic origin [1]. Besides pesticides or heavy metals, pharmaceuticals 
being extensively used for medicinal purposes, belong to these anthropogenic 
substances. They were widely ignored as environmental contaminants until the early 
1990th. Since then, the environmental risk caused by pharmaceuticals has become an 
important issue in environmental sciences [2-8]. Pharmaceutical compounds have 
recently been identified as contaminants in sewage effluents [9-13], surface and 
groundwater [3,14-20]. and even drinking water [21-23]. Concern exists about the 
possible implications for pharmaceuticals becoming distributed in the environment on 
grounds both of toxicity and, in the case of antibiotics, of the development of resistant 
strains of microorganisms [3,12,22-26]. Contamination can arise from many sources, 
including excretion of ingested pharmaceuticals, improper disposal at the consumer 
level, intensive animal husbandry, and inadequate treatment of manufacturing waste 
[25.27].Widespread contamination only occurs when the substances of concern are 
rather recalcitrant towards degradation (e.g. in secondary sewage treatment). This has 
led to an intensive search for methods of chemical degradation, using oxidants such as 
sodium hypochlorite, hydrogen peroxide, and Teuton's reagent (Fe'VH^O:) [28.29]. 
as well as so-called "Advanced Oxidation Processes"' using reagents such as O3, 
O3/H2O2, H2O2/UV and H202/Fe^^/UV [30-35]. 
Recently, there is great interest in the environmental relevance of 
contamination of natural waters by pharmaceutical drugs and their metabolites as 
emerging pollutants. Since thousands of tons of drugs are consumed each year in the 
world, a large number of anti-inflammatories, analgesics, antiepileptics. lipid 
regulators. B-blockers, antibiotics, estrogens, antiseptics and disinfectants has been 
detected in sewage treatment plant effluents, in surface and ground waters and even in 
drinking water at concentration usually ranging from nanograms to micrograms per 
liter. For example, concentrations of the anti-inflammatory paracetamol (N-(4-
hydroxyphenyl) acetamide) up to 10 fig L"' in US natural waters and up to 6 \xg L'' in 
effluents of European sewage treatment plants have been detected [9.36.37]. To avoid 
the dangerous accumulation of drugs in the aquatic environment, research efforts are 
underway to develop powerful oxidation methods that can be applied to ensure their 
complete destruction from natural waters and wastewaters. Although different 
isolation, physical separation, biological and chemical methods can be utilized [38]. 
1.1 Theoretical background 
1.1.1 Pharmacokinetics 
A major factor determining the occurrence of pharmaceuticals in the aqueous 
environment is their pharmacokinetic behaviour which describes the time course of a 
drug and its metabolites in the body after any kind of administration [39]. The 
metabolism of pharmaceuticals occurs in two consecutive phases as shown in Fig. 1.1. 
Phase I reactions involve the formation of new or modified functional groups 
including oxidation, reduction, hydrolysis, hydration, condensation and isomerization 
reactions, which usually all result in an increased polarity. In phase II, the metabolites 
are conjugated with endogenous molecules to obtain elevated water solubility. 
Finally, the water-soluble metabolites are excreted via urine and feces. 
Phase I Phase II 
Xenobitic p. Phase I Metabolite ^ Phase II 
Metabolite Oxidation Conjugation 
Reduction 
Hydrolysis 
Fig 1.1: General scheme for the metabolization of xenobiotic. 
1.1.2 Exposure pathway 
Production and application of human and veterinary pharmaceuticals leads to a 
potential environmental exposure and potentially to an accumulation in certain 
environmental compartments. The main exposure routes of human pharmaceuticals 
are expected to be through their use by patients in private households, in hospitals and 
by disposal of pharmaceuticals through toilets. After their use, pharmaceuticals are 
excreted unchanged and/or as metabolites in feces and urine and hence are present in 
wastewater [40]. Similar to other compounds of anthropogenic origin, the fate of the 
pharmaceuticals residues during sewage treatment can follow one or a combination of 
three types of behavior: (a) bio-degradation (mineralization), (b) sorption of the 
residues onto sewage sludge or (c) no elimination. The latter results in their presence 
in treated wastewater [3,41,42]. 
Hence, compounds that are not readily degradable enter the environment 
either with the digested sludge or as dissolved pollutants in the sewage treatment plant 
(STP) discharges. The latter scenario results in the contamination of the receiving 
waters and finally, the aquatic environment [9,42-51]. 
Pharmaceutical residues have also been found in groundwater. They were 
often traced back either to an impact of municipal or industrial wastewater, animal 
farming, an infiltration of contaminated surface water or landfill seepage over 
vulnerable water aquifers [52-57]. It is further conceivable, that contamination occurs 
with the discharges of the pharmaceutical industry. 
Environmental exposure routes for veterinary pharmaceuticals can mainly be 
attributed with the distribution and application of dung, urine and manure as fertilizer 
from medicated animals [58.52]. Direct carryover into the water compartment from 
medical treatment of aquacultures has also been linked [59-61]. Several research 
efforts are in progress to avoid the accumulation of these pollutants in the aquatic 
environment [62]. The development of oxidation techniques for achieving the 
reduction of water pollution has been proposed [63,64]. Various works have reported 
the successful employment of ozonation and advanced oxidation processes (AOPs), 
such as the O3/H2O2, Fenton, and Ti02/UV systems, for the degradation of 
pharmaceuticals and their metabolites in water [65-68]. 
1.1.3 Occurrence and fate 
Numerous studies have been conducted to investigate various aqueous 
matrices for the presence of pharmaceutical residues, comprising the target 
compounds and metabolites. In fact, these residues have been found to be ubiquitous 
in environmental waters [46,69,70].The main contributing factor for the occurrence of 
pharmaceuticals in the aquatic environment is the elimination efficiency of the 
sewage treatment process [9.50,71-73]. Particular weather conditions, i.e. rainstorm 
events, may result in reduced elimination efficiency [9]. Many pharmaceuticals are 
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excreted to a large extent as transformed phase I metabolites and/or after conjugation 
to hydrophilic groups as phase II metabolites. Conjugates are easily cleaved in the 
sewage treatment plant (STP), causing a re-formation of the original pharmaceuticals 
[50,73,74]. This might lead to higher concentrations in the STP effluent than in the 
raw wastewater. 
Pharmaceuticals are principally designed to persist in the body after 
administration. That might be the reason that many pharmaceuticals are relatively 
resistant towards degradation under environmental conditions and pass through the 
STP without major elimination, such as the lipid regulator clofibric acid, the 
antiepileptic carbamazepine or the contrast medrnm diatrizoate [9,11,75]. 
Residues of various pharmaceuticals are present in the low ^g.L"' range in 
STP effluents. Discharge of the STP effluent into the receiving waters leads to a 
dilution of the pharmaceutical residues which occur up to the high ng.L"' range in 
contaminated surface water. Once introduced into the surface waters, pharmaceuticals 
may undergo biodegradation, most likely due to co-metabolic processes. For some 
pharmaceuticals, i.e. diclofenac, photo induced degradation may occur from natural 
solar radiation [16.76-79]. 
1.1.4 Advanced oxidation processes (AOPs) 
Direct chemical oxidation with H2O2 or ozone is usually not effective for the 
treatment of most wastewaters containing organic pollutants. The alternative use of 
advanced oxidation processes (AOPs) in which 'OH is produced by means of 
chemical, photochemical, photocatalytic or electrochemical reactions is preferred. 
This radical, the second strongest oxidizing species known after fluorine, reacts non-
selectively with most organics leading to dehydrogenated or hydroxylated derivatives 
until their total mineralization (i.e. their conversion into CO2, inorganic ions and 
water). However, the oxidation power of'OH in aqueous medium is limited by its low-
diffusion and reaction with inorganic anions (scavengers) present in wastewaters. 
Among the chemical, photochemical and photocatalytic AOPs, the most usual 
procedures are UV photolysis [80], H2O2/UV [81-83], O3/UV [84,85], O3/H2O2/UVA 
[31.86,87], 03/Fe^^/UVA [88-92], UiOj/Fe^^ (Teuton's reagent) and H202/Fe^*/UVA 
(photo-Fenton method) [92-94]. Fenton's reagent is an acidic solution of H2O2 and a 
3+ Fe' salt that generates "OH and Fe from Fenton's reaction: 
Fe^^ + H202 • Fe^^ + 'OH + OH" (1) 
This catalytic reaction propagates from Fe^ "^  regeneration by reduction of Fe'^. mainly 
with H2O2. The catalytic capacity of Fe^ "^  increases when the solution is irradiated 
with UV light of wavelength between 300 and 420 nm due to: (i) the photolysis of 
Fe'^ ^ complexes with degradation products such as oxalic acid [92], and (ii) the 
increase of the regeneration rate of Fe'^ from the additional photoreduction of Fe 
(OH)' , the main Fe^ "^  species in acid medium, from the following photo-Fenton 
reaction [93, 94]: 
Fe(OH)^" + hv • Fe-^+*OH (2) 
1.1.5 Electrochemical advanced oxidation processes (EAOPs) 
Recently, alternative electrochemical methods are being applied to achieve the 
total degradation of wastewaters containing organics. They are based on: (i) direct 
electrolysis, where pollutants are removed either by direct electron transfer at the 
electrode or through their chemical reaction with generated species that remain 
adsorbed on the electrode surface and (ii) indirect electrolysis, where pollutants are 
destroyed in the bulk solution by active species generated in the electrode. 
The advantages of the electrochemical methods with respect to the chemical 
ones are: (i) environmental compatibility, since the used reagent is the electron, (ii) 
versatility, because pollutants can be treated using different reactors and electrode 
materials of distinct forms and configurations and. in addition, processes can be easily 
scaled from laboratory to plant, (iii) security, given the mild operative conditions 
employed and the small amounts of generally innocuous chemicals used, and (iv) 
energy efficiency, since electrochemical processes are made at low pressure and 
temperature (environmental conditions), using equipment and simple operations with 
low cost. At present chemical (AOPs) and electrochemical (EAOPs) advanced 
oxidation processes with ability to destroy organic pollutants in waters are being 
developed. 
1.1.5.1 Direct electrolysis 
Anodic oxidation is the most common direct electrochemical method [95-99] 
applied to water remediation. It is based on the use of high 02-overvoltage anodes 
favoring the generation of hydroxyl radical as intermediate of the direct water 
oxidation to oxygen, which remains adsorbed at the anode surface: 
H2O • "OH (ads) + H" + e" (3) 
The method is carried out generally in the anodic compartment of a divided 
cell, where the contaminated aqueous solution is degraded using anodes of Pt, 
undoped and doped Pb02, doped SnOa. Ir02, etc. Most organic pollutants are then 
oxidized by *0H electrogenerated at high anode potentials in the region of water 
discharge with simultaneous evolution of O2, thus causing the regeneration of the 
anode surface. Under these conditions, however, many solutions are poorly 
decontaminated by such conventional anodes due to the formation of short-chain 
carboxylic acids that are hardly oxidizable with 'OH. Recent studies have showTi that 
the latter products can be destroyed using a boron-doped diamond (BDD) thin-film 
anode with greater O2 overpotential that produces much higher amount of reactive 
'OH able to react with adsorbed organics up to their complete mineralization. It has 
been shown that the use of Pt [95,96], Ti/Ir02 [100] and Ti/Ru02 [101] anodes in 
anodic oxidation favors the electrochemical conversion of pollutants, whereas the 
alternative treatment with Pb02 [102,103], Ti/Sn02 [103,104] and BDD [105,106] 
anodes leads to their electrochemical combustion. This different behavior has been 
explained by Comninellis and De Battisti [101] for ametallic oxide (MOx) anode. 
These authors consider that the process is initiated by the water discharge gi\'ing the 
MOx('OH) species physisorbed at the anode surface from the following reaction: 
MOx + H2O • MOxCOH) + H^ + e" (4) 
and subsequently, the physisorbed species is oxidized to the chemisorbed one (MOx+i) 
as follows: 
MO,('OH) • MOx+i+H^ + e" (5) 
Both physisorbed and chemisorbed species lead to O2 evolution in the absence of 
organics. However, when a pollutant R is present in the solution, the physisorbed 
species leads to their total mineralization (electrochemical combustion) by the generic 
reaction: 
R + z MOx('OH) • CO2 + H2O + z MOx + z H V z e" (6) 
whereas the chemisorbed species gives rise to the formation of partialh oxidized 
products (electrochemical conversion) as follows: 
R + MOx+i • RO + MOx (7) 
In the case of the BDD anode the formation of physisorbed species and its reaction 
with organics until total combustion are favored. 
1,1.5.2 Indirect electrolysis 
More potent indirect electrooxidation methods involving H2O2 
electrogeneration such as electro-Fenton and photoelectron-Fenton are also bemg 
developed to destroy toxic aromatic pollutants in acidic wastewaters. These latter 
methods and anodic oxidation with BDD, so-called electrochemical advanced 
oxidation processes (EAOPs), are environmentally friendly technologies. In the above 
indirect electrooxidation methods hydrogen peroxide is continuously generated m the 
contaminated solution from the two-electron reduction of oxygen at graphite [107], 
reticulated vitreous carbon [108,109], carbon-felt [110-112] and 02-diffusion [113-
118] cathodes: 
02 + 2H^+2e" • H2O2 (8) 
When a one-compartment cell is utilized, pollutants can be oxidized by 
electrogenerated H2O2, 'OH formed at the anode surface from reaction (3) and the 
weaker oxidant hydroperoxyl radical (HO2*) produced during the anodic 
decomposition of H2O2: 
H2O2 •H02"+H^ + e~ (9) 
HO2' • 02 + H^ + e~ (10) 
This procedure is known as anodic oxidation with H2O2 electrogeneration. The 
electro-Fenton process involves the enhancement of the oxidizing power of the above 
electrolytic system by adding small amounts of a catalyst like Fe^ .^ which reacts with 
electrogenerated H2O2 to yield 'OH in solution from Fenton's reaction (1). The most 
popular electro-Fenton method is the so-called electrogenerated Fenton's reagent 
(EFR) [107,110-112], where O2 is bubbled through the solution to be reduced to H2O2 
at the cathode surface. Another, electro-Fenton process has been developed using a 
one-compartment electrolytic cell with a Pt or BDD anode, a carbon-
polytetrafluoroethylene (PTFE) 02-fed cathode (02-diffusion cathode) and an acidic 
contaminated solution containing a small amount of Fe^* as catalyst [113-118]. Under 
these conditions, organic pollutants are mainly destroyed by the combined action of 
'OH generated at the anode from reaction (3) and in the medium from Fenton"s 
reaction (1). The O2 diffusion cathode allows a rapid accumulation of H2O2 in 
solution, which quickly produces 'OH radicals through reaction (1), the Fe'^ ion being 
continuously regenerated from the reduction of Fe'^ "^  species: (i) at the cathode, (ii) 
with H2O2, (iii) with HO2' and (iv) with intermediate organic radicals. 
In the photoelectro-Fenton process the degraded solution is also irradiated 
with UV light to enhance the regeneration of Fe ^ through reaction (2). In addition, 
the mineralization process can be accelerated by the photodecomposition of Fe'" 
complexes with some acids, thus allowing regenerating more Fe'"^  [92]: 
Fe (OOCR) ^^  + hv • Fe^"+C02 + R' (II) 
It has been demonstrated that EAOPs are useful for the degradation of aromatic drugs 
and can be applied to the treatment of wastewaters containing these pollutants [119]. 
1.1.6 Degradation products 
The definition of degradation product in the ICH guideline is "a molecule 
resulting from a chemical change in the substances brought about over time and/or 
action of, e.g. light, temperature, pH, or water or by reaction with excipient and/or the 
immediate container/closure system". On the basis of this definition it is difficult to 
draw a clear-cut line between real degradation products and some impurities. The 
question to be answered is when do the "chemical changes" characterized as 
degradation begins. In many cases the chemical transformation of the end product 
already begins in the reaction mixture before its isolation leading to impurities. The 
quantity of these impurities (degradation product) in the end product often increases 
during storage or stress conditions. In other cases this does not take place and entirely 
new degradation product appear. 
The design of a complete stability testing programme for a drug or 
nutraceutical product is based upon an understanding of the behavior, properties and 
stability of the drug substance or active ingredient and experience gained from 
preformulation studies and early clinical formulations. Products are analyzed at 
specific intervals to evaluate a variety of parameters, such as the identity of the active 
ingredient, potency, measurement of degradation products, dissolution time, physical 
properties and appearance. 
1.2 Kinetic methods 
Kinetic automatic methods are good choices for drug analysis as they permit 
the sensitive, selective determination of many drugs within a few seconds with no 
pretreatment. Moreover, the instrumentation required is generally very simple. Kinetic 
methods rely on measurement of concentration changes (detected via signal changes) 
in a reactant (which may be the analyte itself) with time after the sample and the 
reagents have been mixed. The sample and the reagent can be mixed manually or 
automatically and the kinetic curve can be recorded immediately. The slope of the 
straight initial portion of the kinetic curve gives the reaction rate, which is 
proportional to the analyte concentration (initial-rate method). 
PARACETAMOL 
The subject of the present investigation is acetaminophen (also known as 
paracetamol or N-(p-hydroxyphenyl)acetamide), is a non-steroidal anti-inflammatory 
drug (NSAID) belonging to the chemical family of aromatic amides, h is classified as 
a common analgesic and antipyretic drug, analogous to acetylsalicylic acid. In fact, it 
is the most widely used over-the-counter analgesic all over the world [120]. 
Paracetamol is a metabolite of phenacetine, a very commonly used analgesic in past 
years. Due to the fact that phenacetine is really toxic at therapeutical dosage and since 
it is metabolized to paracetamol, phenacetine is no longer used at present. 
HO 
-NH 
H.C 
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Fig 1.2: Paracetamol 
Paracetamol is usually a white crystalline powder, odourless and bitter-tasted. 
Saturated solutions are slightly acid. It is soluble in acetone, hardly soluble in ether or 
benzene and highly soluble in water as shown in Table 1.1. Some of the most 
remarkable properties of paracetamol are also given in Table 1.1. 
Table 1.1 Paracetamol data [121] 
CAS number 103-90-2 
Generic names 
Trade names 
Molecular formula 
Molecular mass (g mol" ) 
Melting point (°C) 
Boiling point (°C) 
Solubility in H20(gL"') 20 °c 
Density (gcm'^) 2 i°c 
pKa 
4-Hydroxyacetanilide4-Acetamidophenol 
Acetaminophenol 
APAP, Disprol. Panadol, Tylenol 
C8H9O2 
151.17 
169-171 
>500 
14 
1.293 
9.71-9.84 
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Paracetamol is a well-known pain reliever, but at the same time when reaching 
a certain dosage it can effectively control Brown Tree Snakes or cause hepatoxicity in 
human beings. Considering this theorem in combination with the fact that the 
environment contains countless organisms with different sensitivities lead to the 
hypothesis that medicines may also pose a risk to the environment. 
In 1994, 153.9 million paracetamol doses were prescribed. It has been 
previously said that the key for considering PPCPs as a matter of ecological concern 
is their continuous introduction in the environment due to their widespread huge 
usage. Undoubtedly, in spite of being considered as readily degradable {ha < 1 day), 
the enormous amount of paracetamol, which is manufactured and released to the 
environment can pose a risk, yet unknown at present, to both humans and animals. 
Indeed, paracetamol occupies almost 50% Of market shares in analgesic-antipyretic 
field of the world and its demand can be up to 70000 tons annually. At. present, the 
international demand is growing at 15% of annual increasing rate. According to recent 
reports it is estimated that by 2010 the annual consumption all over the world will be 
over 100000 tons. More information on paracetamol sales data is available through 
several books [122,123]. 
Before carrying out the present thesis, some previous studies on the 
degradation of paracetamol had been performed by Vogna et al. [81] and Andreozzi et 
al. [124] by means of ozonation and H2O2/UV in the pH range 2.0-5.5. A detailed 
discussion about the intermediates formed in both cases is carried out by these 
authors. Despite the fact that these procedures can be applied to destroy the parent 
molecule, the maximum mineralization achieved is about 30-40%. so more effective 
methods must be tested to avoid widespread contamination. In this sense, the 
electrochemical process can be environmentally friendly alternative. Some literature 
available on the subject clearly reflects the great interest about the role of PPCPs in 
the environment, paracetamol in particular. The limitations of simple ozonation and 
photolytic ozonation (O3/UV) has been overcome by means of catalyzed ozonation 
with Fe^ "", Cu^^ and UVA light [125].More than 83% of mineralization is attained 
with the catalyzed methods. As proved for electron-Fenton and photoelectron-Fenton 
processes. 
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Transformation of paracetamol by chlorination has been studied by Bedner et 
al. [120] to simulate waste water disinfection and understand the toxicological nature 
of the chlorine-transformation products. Worrisome chlorination products such as N-
acetyl-p-benzoquinone imine, which is the toxicant associated with lethality in 
paracetamol overdoses, have been characterized. Due to its lack of stability, the imine 
readily hydrolyzes to the toxicant 1,4-benzoquinone in aqueous solution. 
Bunce et al. [126] have compared the electro-oxidation process (i.e., anodic 
oxidation process) of paracetamol by using BDD, Ti/SnOa and Ti/Ir02 anodes, 
working in an electrochemical reactor. The former two ones led to electrochemical 
combustion, whereas in the latter p-benzoquinone was the exclusive product except at 
very long electrolysis times. 
Paracetamol has been found in sewage effluents at concentrations up to 6.0 \xg 
L"' [9]. This compound may also enter the envirormient from manufacturing wastes 
[127]. Andreozzi et al. [124] oxidized acetaminophen using ozonation or photolysis of 
hydrogen peroxide, both of which achieved complete removal of the substrate as well 
as partial mineralization: 30% for ozonation and 40% for H2O2 photolysis. Ozonolysis 
at the aromatic ring led to the formation of hydrogen peroxide and aliphatic acids, 
such as glyoxylic, oxalic, and formic acids. The peroxide/UV system gave 
hydroquinone and 2-hydroxy-4-(N-acetyl)-aminophenol as intermediates; further 
oxidation gave several products, including (from hydroquinone) 1,2.4 
trihydroxybenzene and a mixtureof oxalic, malonic, and succinic acids. Vogna et al. 
[81] used GC-MS and '^N NMR to track the nitro genous products of UV/H2O2 
oxidation of acetaminophen, among them 4-acetylaminocatechol and acetamide. Sires 
et al. [128] recently studied acetaminophen mineralization at pH 3, using 
electrochemical variants of Fenton and photo-Fenton chemistry in which hydrogen 
peroxide was generated by reduction of O2 at a gas-diffusion carbon-PTFE cathode. A 
drawback to the use of iron salts was resistance to degradation of the iron complexes 
of aliphatic carboxylic acids formed'as intermediates, and no better than 76% 
mineralization, based on total organic carbon (TOC) remaining in solution, could be 
achieved. 
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The results indicate that paracetamol is eliminated from the water phase in the 
water/sediment system. It can be suggested from the rapid and extensive binding onto 
the sediment that paracetamol, but more likely its TPs, are incorporated into the 
biomass and may potentially accumulate in sediments. Since paracetamol or its TPs 
were not extractable, even not under drastic conditions, it can be expected that the bio 
availability in the sediment is low. Consequently, following the classification of Beek 
[129], paracetamol has to be considered as highly persistent in the water/sediment test 
system. However, taking into account what is known about this substance a 
categorization with "low persistence" is more likely. However, a profound assessment 
can only be done after elucidation the nature of the non-extractable residues. No DT-
values for paracetamol in the water/sediment system could be calculated. 
The mechanism of chemical oxidation of acetaminophen involves formation 
of the quinonemethide N-acetyl-pbenzoquinoneimine. which is unstable with respect 
to hydrolysis to benzoquinone and acetamide - the latter previously reported by 
Vogna et al. [35] in the increasingly acidic environment formed as the electrolysis 
proceeds. 
NH.CO.CH, 
-2e' 
-2H* 
OH 
N.CO.CH3 O 
H9O 
O o 
+ NH..CO.CH, 
However, recent work has demonstrated that mineralization of simple phenols 
is possible at electrodes that function mechanistically by production of hydroxyl 
radicals. Phenols substituted with o- and p-electron-donating groups are oxidizable 
electrochemically even at active electrodes such as platinum [98]. This effect is 
especially marked in the case of the aminophenols: the p-isomer oxidized smoothly to 
hydroquinone/benzoquinone, the o-isomer gave a conducting polymer, and the m-
isomer gave a non-conductive polymer that fouled the electrode [130]. As the N-
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acetyl derivative of/'-aminophenol. acetaminophen displays behavior intermediate 
between that of p-aminophenol and the parent compound phenol. 
The degradation of such compound have been conducted by using the 
following oxidative systems: O3/H2O2/UV [81,131], O3AJV plus Fe""^ or Cu"^ as 
catalysts [91], electrogenerated H2O2/UV with Fe^ '*^ or Cu^^ as catalysts [118], and 
anodic oxidation with a boron-doped diamond electrode [106]. The previous v '^orks 
have been reported on the degradation of paracetamol in aqueous solution by the 
Ti02/UV oxidative system, although a related study on the H202/Ti02 photocataljlic 
oxidation of metal (an structurally-related molecule) has been performed. The 
products resulting from such photocatalytic oxidative process are characterized via 
GC/MS analysis of the derivatized samples [132]. 
Degradation of paracetamol 
The degradation of paracetamol (1) in aqueous solution by Ti02/UV was 
initially monitored by UV-Vis spectroscopy. The UV-Vis spectra (not shown) 
undergo changes as the reaction proceeds. The absorption maximum at the two 
characteristic wavelengths of 1, i.e. ca. 195 and 243 nm, continuously decreases. 
After 150 min of reaction, the UV-Vis spectra show only an absorption band at 210-
190 nm. The oxidation of paracetamol is of interest in view of the importance of 
understanding the mechanisms of metabolic conversion of paracetamol in biological 
systems. Paracetamol is primarily metabolized [133] by the li\'er. Most of it is 
combined with glucuronide and sulphate, which account for about 90% of the dose 
excreted. About 5% of the dose is excreted unchanged and a further 5% is oxidised to 
a benzoquinoneimine, which is then combined with glutathione and metabolised on to 
cysteine and mercapturate compounds, which are safely excreted. 
For paracetamol, concentrations up to 6 ^g L'' have been detected in STP 
effluents. Although there has been no proof that very low amounts of pharmaceuticals 
in natural waters had any adverse health effects, they can produce toxic effects to 
aquatic organisms and in the case of antimicrobials, the development of multi-
resistant strains of bacteria [32]. To avoid the dangerous accumulation of drugs in the 
aquatic environment, research efforts are underway to develop more powerful 
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oxidation methods tlian tliose currently applied in wastewater treatments for achieving 
their complete destruction. 
Ozonation and some advanced oxidation processes (AOPs), such as 
O3/H2O2, H2O2/UV and H202/Fe^" /^UV, have been successfully used to remove 
several common pharmaceuticals in aqueous media [31-33,67,81.83.98.134.135]. The 
great effectiveness of AOPs is due to the production of hydroxyl radical ('OH), which 
is a non-selective, very powerful oxidizing agent able to react with organics giving 
dehydrogenated or hydroxylated derivatives, up to their complete mineralization is 
reached. The most usual technique is anodic oxidation, where solutions are 
decontaminated during electrolysis by the direct reaction of pollutants with adsorbed 
•OH formed at the anode surface from oxidation either of water in acid and neutral 
media or hydroxide ion at pH >10 [97-99]: 
H2O • 'OHads + H^ + e- (18) 
OH- *' •OHads + e- (19) 
The kinetics of the oxidation of ruthenium(III) and osmium(VIII) catalysed 
oxidation of paracetamol by diperiodatoargentate(III) (DPA) in aqueous alkaline 
medium at a constant ionic strength of 0.10 mol.dm'^ was studied 
spectrophotometrically. The reaction between DPA and paracetamol in alkaline 
medium exhibits 2:1 stoichiometry in both catalysed reactions (DPA:PAM) [136]. 
The oxidation of organic reductants by permanganate in aqueous media has received 
considerable attention [137-146]. It has become clear that when manganous and 
organic substrates are initially present in excess, the reaction involves two processes 
[147-151]. 
Reductant 
MnO; ^ Intermediate (s) (20) 
Reductant 
Intermediate (s) • Mn(II) (21) 
15 
In alkaline or weakly acidic solution, permanganate changes to Mn(lV). while 
in strongly acidic medium, permanganate is further reduced, forming Mn(ll). It has 
been reported on several occasions that the intermediate (Mn(IV)) could be H2Mn04. 
H2Mn03, or a water-soluble colloidal Mn02 [152-155]. The Mn02 appears practically 
only after MnOj has completely disappeared from the system. In the case where 
permanganate serves as an oxidizing agent in acid medium, the possible intermediate 
species are Mn(VI). Mn(V), Mn(III), and Mn(IV). On the other hand, Mn(II) (reaction 
product) acts as autocatalyst. Therefore, the MnO;^  oxidations provide chemical 
kinetics with challenging mechanism to possibilities due to the ability of Mn to exist 
in a multitude of oxidation states. Several spectroscopic methods for its determination 
based on the oxidation have been reported [156-158]. Information regarding the 
formation of water-soluble colloidal Mn02 (brown-yellow product) has been reported 
[159]. 
DICLOFENAC SODIUM 
Diclofenac sodium (Fig 1.2). (die), is monosodium 2-[(2,6-dichloroanilino) 
phenyl] acetate, a potent and highly active (NSAID) possessing very powerful 
analgesic effects [160]. In the United Kingdom, India, and the United States, it may 
be supplied as sodium or potassium salts, while in some other countries only as the 
potassium salt. Diclofenac is available as a generic drug in a number of formulations. 
,CH2C00Na 
Fig 1.2: Diclofenac sodium 
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Diclofenac, a phenylacetic acid derivative, is a nonsteroidal anti-inflammatory 
analgesic with potent cyclooxygenase inhibition activity [161.162]. This drug is 
commonly used for pain control and the treatment of rheumatic diseases [163]. This 
excessively high activity was established experimentally by Jobin and Gagnon [164] 
and assessed by Kenawi via ab initio theoretical calculations [165]. New derivatives 
of this drug are continually being investigated by pharmacologists [166]. Therefore, 
invaluable data to be added to its profde [167.168]. 
Diclofenac is well absorbed after oral administration with extensive hepatic 
metabolism [169,170]. This compound exhibits a terminal half-life of 1-2 h, volume 
of distribution of 0.17 1/kg, and 99% protein binding [171-173]. Several unwanted 
adverse effects are generally associated with the long term oral administration of 
NSAIDs, including stomach ulcerations, abdominal burning, pain, cramping, nausea, 
gastritis, and even serious gastrointestinal bleeding and liver toxicity. The sodium 
diclofenac is completely absorbed following oral administration, but its elimination 
half-life is relatively short. 1-2 h [174]. Gastrointestinal side effects such as bleeding, 
ulceration or perforation of intestinal wall are commonly seen [175-177]. Due to short 
biological half-life and associated adverse effects, it is considered as an ideal 
candidate for controlled drug delivery [178]. 
The literature reports some data on chemical and spectroscopic characteristics 
of DS [179-181] and several methods for its determination of degradation products in 
drug formulations. They include thin-layer (TLC) [182], high-performance liquid 
(HPLC) [183], gas chromatography (GC) [184] and densitometric [185] methods. 
TLC offers great resolution and speed, but suffers quantitative accuracy. Although 
HPLC provides the possibility for a sensitive and accurate procedure for the 
determination of degradation products, the investigated sample requires fractionation 
and purification. Densitometnc measurements allow determination of degradation 
products at trace levels, but they are useful in particular when a small number of 
samples have to be analysed [185]. Gas Chromatography is a fast, efficient and 
accurate technique for the analysis of mixtures but it requires a derivatization step. 
Some of the GC procedures are based on the formation of an indolinone derivative, 
which is one of the degradation products of diclofenac sodium [183]. It should be 
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noted however, that the analytical methods, except HPLC. do not appear capable of 
distinguishing between intact drug and the indolinone cyclization product [186]. 
In order to eliminate the preliminary clean-up procedure, it was decided to 
examine the possible application of UV derivative spectrophotometric method for 
determination of degradation products of diclofenac sodium. Different methodologies 
have been proposed for the determination of sodium diclofenac in pharmaceutical 
formulations, namely spectrophotometry [187-205], fluorimetry [206-209], 
potentiometry [210-213], chromatography [214-216], and nuclear magnetic resonance 
spectroscopy [217]. Diclofenac sodium contains not less than 99.0 percent and not 
more than the equivalent of 101.0 percent of sodium 2-[(2.6-dichlorophenyl) 
amino]phenyl]acetate, calculated with reference to the dried substance. 
The more simple, rapid and sensitive are those based on the direct UV 
spectrophotometry, because the procedures involve neither complicated and time-
consuming sample treatments nor the need of special reagents. However these 
methods may produce wrong results specially if an unexpected interference occurs 
(e.g. a degradation product that absorbs at the selected wavelength). For this reason it 
is essential to check if a sample may be analysed accurately by a method providing a 
final verification of the results. 
Diclofenac sodium is a white powder fairly soluble in water. The aqueous solution has 
nearly neutral pH (about 7.7 for 0.1% w/v). is stable for two weeks at least (checked 
by UV spectrophotometr>') and shows a characteristic spectrum (Fig. 1.3), with two 
absorption bands with maxima at X= 200 mn and X = 276 nm. Reddish-purple 
coloration is produced in presence of a strong oxidizing agent [218]. 
The occurrence of pharmaceuticals in the environment is an emerging issue. 
Several studies obser\'ed that the non-steroidal anti-inflammatory drug diclofenac 
sodium is ubiquitously present in most of the surveyed surface waters, worldv\ide. 
Phototransformation of diclofenac was reported from laboratory assays as well as in 
natural water systems, raising the question of possible adverse effects of the 
phototransformation products of diclofenac to aquatic organisms. It has been 
concluded that toxicit>- assessment of phototransformation products should be 
included in the risk assessment of pharmaceuticals in the environment [219]. Ternes 
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[9] demonstrated that a majority of human drugs passed through sewage treatment 
plants and occurred in streams and rivers in low-level concentrations ranging from ng 
L ' to^igL^'. 
200 220 240 260 280 300 
Wavelength (nm) 
320 340 
Fig. 1.3: UV absorption spectra of Diclofenac sodium in aqueous solution. 
To date, no extensive biodegradation study of diclofenac has been reported. 
However, degradation has been reported to occur only via photolysis [16] or oxidation 
using ozone [220]. The occurrence of diclofenac in waste treatment facilities and 
receiving bodies of water likewise demonstrates the compound's slow degradability 
and it is therefore considered an environmentally relevant concern. In conclusion, the 
results show that diclofenac inhibits many microorganisms that would usually 
comprise a lotic biofilm [221]. This was confirmed by in situ observation (CLSM) of 
the biofilms exposed to diclofenac as well as by microbiological analyses using 
isolation techniques and by molecular methods (FISH). Diclofenac therefore asserts 
itself as an environmental concern due to its prevalent use. The results of the chemical 
analysis for diclofenac degradation supported the findings that diclofenac disrupts 
'normal' biofilm development. Previous work has shown that direct photohsis is the 
dominant degradation mechanism for diclofenac [15.16.76.222-224]. The aim of the 
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present study was to develop a simple, sensitive and rapid UV-spectro-photometric 
method for degradation of Diclofenac sodium. 
The present work is devoted to the study of the degradation of the non-
steroidal anti-inflammatory drug (NSAID) paracetamol and diclofenac sodium 
divided into four parts: (I) an introduction giving an overview on the characteristics of 
these drugs, their environmental relevance and some results published in literature on 
their degradation (ii) the results obtained on the oxidative degradation of paracetamol 
by permanganate in neutral medium- a kinetic and mechanistic pathways, (iii) the 
results obtained by studying kinetics and mechanism of oxidative degradation of 
paracetamol by potassium dichromate in acidic medium, and (iv) the results obtained 
for the oxidative degradation of Diclofenac sodium by permanganate in neutral 
medium- a kinetic and mechanistic pathways. 
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CHAPTER-II 
Oxidative Degradation of Paracetamol by 
Permanganate in Neutral Medium-A 
Kinetic and Mechanistic Pathway 
2.1 INTRODUCTION 
Paracetamol (4'-hydroxy acetanilide or acetaminophen or 4-acetamidophenol) 
(PAM) is a well-icnown drug that finds extensive applications in pharmaceutical 
industries. It is an antipyretic and analgesic compound [1] that has high therapeutic 
value. It is the most widely used medicine worldwide for the relief of pain associated 
with headache, backache, and postoperation. On the other hand, when consumed in 
overdose, it may cause severe hepatic toxicity or death. It is used as azo djes, as a 
stabilizer for hydrogen peroxide, and as intermediate for pharmaceuticals (as a 
precursor in penicillin). It is also used as an alternative to aspirin. There is hardly any 
work reported with regard to the kinetics of oxidation of this drug in literature except 
for two cases [2,3]. 
The oxidation by KMn04 finds extensive application in organic synthesis [4-
9]. During oxidation by KMn04, in acidic, alkaline and neutral media the species 
manganese is reduced to various oxidation states. The oxidation of organic reductants 
by KMn04 in aqueous media has received considerable attention [10-19]. In those 
cases where permanganate serves as an oxidizing agent in acid medium; the possible 
intermediate species are Mn (VI). Mn (V). Mn (III), and Mn (IV). On the other hand, 
Mn (II) (reaction product) acts as auto catalyst. Therefore, the MnO^ oxidations 
provide chemical kinetics with challenging mechanism to possibilities due to the 
ability of Mn to exist in a multitude of oxidation states. Several spectroscopic 
methods for paracetamol determination based on the oxidation have been reported 
[20-22]. 
Our investigations provide a detailed process-level understanding of the 
oxidative degradation of paracetamol by permanganate. The specific objectives are (a) 
to examine reaction order, degradation rate and kinetic behavior of paracetamol in 
reaction with permanganate, (b) to demonstrate the extent of degradation, and (c) To 
investigate the reaction at different temperatures which allows the determination of 
the activation parameters with respect to the slow step. 
2.2. EXPERIMENTAL 
2.2.1 Apparatus 
Thermo spectronic Genesis 20 UV-visible spectrophotometer with matched 
quartz cells was used to measure absorbance. A high precision water bath was used to 
control the heating temperature for color development. 
2.2.2 Reagents and standards 
All reagents and chemicals used were of analytical grade. Potassium 
permanganate (GR Grade. Merck Limited, Mumbai. India) was prepared in deionized 
water. The drug, paracetamol (Glaxo. Batch no. FB-CRT-15-4-05) was used in the 
study. Deionized water was used throughout the experiment. 
2.2.3 Sample solution of paracetamol 
Two tablets were powdered and weighed. The powder equivalent of 0.01 gm 
of active ingredient was stirred well with deionized water for 30 min. and filtered 
through Whatmann No. 42 filter paper (Whatmann International Limited, Kent, UK). 
The residue was washed well with deionized water for complete recover^' of the drug. 
The content of the drug was then diluted to 50 ml. It was further diluted according to 
the need and subjected to the degradation procedure for paracetamol. 
2.2.4 Preparation of KMn04 solution 
KMn04 (0.040 gm) was quantitatively transferred into a 25 ml standard flask, 
and makeup with distilled water. Potassium permanganate solution is freshly 
prepared. The solution of KMn04 was stored in a dark glass bottle. 
2.2.5 Kinetic Procedure 
The oxidation of paracetamol by permanganate was followed under pseudo-
first order conditions. The spectrophotometric kinetic studies were performed on the 
basis of the absorbance (optical density) noted at Xma\ (wavelength) as a function of 
time. These reading were conveniently made with a Genesis 20 spectrophotometer for 
relatively slow reactions. The sample was withdrawn from the thermostated reaction 
mixture for measurement. The reaction was initiated by mixing the required quantities 
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of paracetamol and KMn04 at desired temperature in the range (25-55 °C). The 
progress of the reaction was observed spectrophotometrically by pipetting 
out aiiquots at different time intervals and measuring the change in the absorbance 
at its Xma\ 525 nm. 
In order to obtain spectroscopic characteristics of intermediates or products 
formed during the reactions, the reaction solution was successively scanned by a UV-
visible spectrophotometer (UV mini 1240 Shimadzu). 
2.3. RESULTS AND DISCUSSION 
2.3.1 General considerations 
The limiting logarithmic method [23] was used for the determination of the 
molar ratio between KMn04 and PAM in the reaction. This method depends on 
measuring the optical densities of solutions of KMn04 and PAM in which the 
concentrations of the two species are varied. The ratio may be found by plotting the 
logarithms of the absorbance (A) of the two sets of solutions versus composition, one 
with constant KMnOa concentration and variable PAM concentration, the other with 
constant PAM and variable KMn04 concentration. The slope of the curve in case 1 
yields the number of moles of PAM while that in case 2 give the number of moles of 
KMn04 and so the composition of the compound produced can be evaluated. The 
molar ratio was found to be 1:2 for PAM and KMn04 To examine the effect of 
variables, experiments were carried out under pseudo-first order conditions. 
2.3.2 Degradation of [Mn04"] and [Paracetamol] 
In order to investigate the kinetics of paracetamol - Mn04 reaction, a series of 
experiments were carried out under pseudo-first order conditions. [Paracetamol] is 
varied from O.lxIO"^  to 1.0x10""^  mol.dm"^  at constant [MnO;] 0.6x10"-' mol.dm"-' 
(Table 2.1). The kobs [Paracetamol] plot is linear passing through the origin, indicating 
first-order dependence on [Paracetamol]; Fig. 2.1 depicts the dependence of kohs on 
[Paracetamol] at constant [MnO;^]. The pseudo-first order rate constants kobs, min' 
were calculated from the slopes of plots of log Abs vs time Fig. 2.2. The degradation 
of permanganate is also shown, [MnO^] varied from 0.3x10'^  to 1.0x10"^  mol.dm"^ , at 
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Table 2.1: Variation of pseudo-first-order rate constant (kobs) for the oxidation of 
paracetamol by MnO^ at 525 nm, [MnO^ ] = 0.6x10'^ mol.dm'\ Temp = 35 V . 
Drug Conc.xlO"'moI.din'^ kobs^ l^O'^ min' 
Paracetamol OT 0.4 ±0.000 T 
0.2 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1.0 
2.1 ±0.001 
2.5 ± 0.002 
3.0 ±0.002 
4.3 ± 0.003 
4.8 ±0.004 
6.3 ± 0.004 
7.6 ±0.005 
9.7 ± 0.004 
b Error limits are standard deviations. 
Table 2.2: Variation of pseudo-first-order rate constant (kobs) for the oxidation of 
paracetamol by MnO;; at 525 nm, [PAM] = 0.5xlO'^mol.dm'\ Temp = 35 °C. 
Oxidant Conc.xlO'^ mol.dm"^ kobs ^  lO'^min' 
Potassium permanganate "or 8.8 ± 0.009* 
0.3 8.3 ±0.006 
0.4 4.8 ± 0.004 
0.5 4.2 ± 0.003 
0.6 3.2 ±0.002 
0.7 3.2 ±0.002 
0.8 2.7 ±0.002 
0.9 2.4 ±0.002 
1.0 2.3 ±0.002 
b Error limits are standard deviations. 
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Fig. 2.2: log absorbance-time curves for the reaction between paracetamol and 
KMn04 in aqueous medium: [MnO 4] = 0.6x10'^ mol.dm"^ and 
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-4 1 
constant [Paracetamol] 0.5x10 mol.dm' . It is observed that as the initial [MnO;^] 
was increased, the value of kobs decreased (Table 2.2). The abnormal behavior 
probably was due to possible flocculation of colloidal particles. 
2.3.3 Oxidation kinetics 
Kinetic experiments of oxidation of PAM with permanganate were conducted 
at a constant temperature of 25° C under dark conditions. The PAM degradation 
curves are shown in Figs. 2.3 and 2.4. In Fig. 2.3 the initial permanganate 
concentration was held constant at 0.6x10' mol.dm" and the initial PAM 
concentration was varied (0.4, 0.5, 0.6, and 0.7)xl0 mol.dm' . Fig. 2.4 shows the 
degradation of PAM at four different initial permanganate concentrations (0.3, 0.4, 
0.5, and 0.6)xl0'^ mol.dm'^ with a constant initial PAM concentration of (0.5x10'^ 
mol.dm'^). It is evident from Figs. 2.3 and 2.4 that PAM degraded faster at higher 
concentration of PAM and permanganate. As can be expected, the plots of 
concentration versus time could be fitted to an exponential curve in all cases. The 
degradation of PAM can be described with the following general rate equation 
r = -1 /a (d [PAM]/dt) = k [PAM]' [permanganate] ^ (1) 
When the concentration of [permanganate] is in excess, Eq. (1) can be simplified as 
Eqs. (2) and (3). 
r = kobs [PAM]'' (2) 
kobs ^ k[permanganate] ^ (3) 
where r is a reaction rate, k the rate constant, [PAM] and [permanganate] the 
concentrations of PAM and permanganate, respectively, x and y are the orders of the 
reaction with respect to each reactant. kobs is a pseudo-order rate constant because 
[permanganate] is effectively constant during the course of experiment. By varying 
the values of [PAM] and measuring reaction rate, the order x with respect to [PAM] 
can be simply determined by a log-log form of Eq. (2): 
log r = log kobs + X log [PAM] (4) 
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In a similar way but varying initial concentration of [permanganate] and measuring 
kobs, the order y with respect to [permanganate] can he obtained by a log-log form of 
Eq. (3): 
log kobs = log k + y log [permanganate] (5) 
To minimize the errors from competitive reaction that may be induced using 
integral method, the initial rate method was used to measure the rate parameters of 
reaction. At the beginning of the reaction both of PAM and permanganate 
concentrations are known. The PAM and permanganate concentrations and the 
calculated rate constants are summarized in Table 2.3 and Table 2.4. The initial 
reaction rates were determined from the tangent of the PAM concentration-time curve 
in Figs. 2.3 and 2.4 at t=0. 
The two sets of kinetic experiments were designed to calculate x and y values 
for PAM oxidation. The first set of four experiments was conducted with initial PAM 
concentrations varying (0.4, 0.5, 0.6, and 0.7)xl0 mol.dm" . The initial 
permanganate concentration was fixed at 0.6x10' mol.dm' for all experiments. The 
initial reaction rates were determined as the tangent to the PAM concentration-time 
curve. The rate at which PAM is degraded can be simply measured when the other 
reactant, permanganate, is held essentially constant throughout the experiment. In Fig. 
2.5 the log of initial rates versus the log of the initial PAM is shown. The slope of the 
calculated linear regression gave the rate order x = 0.8056 (~1), indicating that the 
reaction is also first order reaction with respect to PAM concentration. 
In the second set of four similar experiments, the initial concentration of PAM 
was fixed at (0.5x10"* mol.dm'^) and PAM was reacted with permanganate ranging 
from (0.3, 0.4, 0.5 and 0.7)xl0'^ mol.dm" .^ Fig. 2.6 shows the log of the pseudo-first-
order rate constant (kobs) versus the log of initial permanganate concentration. The 
slope of regression line is y = 1.0864 (~1), indicating that the reaction is first-order 
with respect to the permanganate concentration. 
From Fig. 2.6. the rate constant for the overall reaction can be calculated. The 
y-intercept of the gradient (-5.9485) is the antilog of the second order rate. Thus, Eq. 
(1) can be rewritten as Eq. (6). The results indicate that the overall reaction is a 
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Table 2.3: Effect of [PAM] on the Ro for the oxidation of paracetamol with 
[MnO; ] = 0.6x 10"^  mol.dm"\ Temp = 35 °C. 
[PAM] X lO'*mol.dm"^ ro x 10'mol.dm^min"' R 
0.4 2.74 0.9853 
0.5 3.30 0.9887 
0.6 3.95 0.9882 
0.7 4.24 0.9763 
0.8 4.61 0.9834 
0.9 5.00 0.9841 
1.0 5.23 0.9553 
Table 2.4: Effect of [MnO 4] on the Ro for the oxidation of paracetamol with 
[MnO;], [PAM] = 0.5xlO-^mol.dm"^ Temp = 35 "^ C. 
[MnO; ] X 10"^  mol.dm'^ ro x 10 ^  mol.dm ^min"' R 
0.3 2.85 0.9784 
0.4 3.11 0.9865 
0.5 3.19 0.9806 
0.6 3.36 0.9904 
0.7 3.58 0.9875 
0.8 3.80 0.9889 
0.9 3.89 0.9854 
1.0 3.85 0.9853 
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second-order reaction and first-order reaction with respect to both permanganate and 
paracetamol. 
r = 1.13 X10"^  [PAM] [permanganate] (6) 
The first-order reaction rate with respect to the initial PAM concentration is also 
confirmed in Fig. 2.7, where the log of PAM/PAMQ versus time of four different 
inifial PAM concentrations is shown. The slope of the linear regression shows a linear 
relationship, indicafing first order with respect to the PAM concentration. Similarly, at 
different initial dichromate concentrations, the log of permanganate/permanganatCo 
versus time (Fig. 2.8) also shows a linear relationship, demonstrating first order with 
respect to the PAM concentrafion as well. 
2.3.4 Chemical oxidation of paracetamol and permanganate 
To obtain the different kinetic parameters for degradation of PAM and 
KMn04 and to get a rate expression (Ro) for oxidation of PAM with potassium 
permanganate, a systematic approach was considered to establish the dependence of 
Ro on [PAM] and [MnO^]. A change in concentration of paracetamol in the range of 
(1x10"^ to lxlO"^)mol.dm'^ was done to study the course of oxidation while keeping 
the [MnO^ ] (0.6x10" mol.dm"). The plots were obtamed for absorbance versus time 
for the course of oxidation of paracetamol with potassium permanganate. They were 
almost similar and showed the time dependence growth of absorbance at 525 nm. For 
paracetamol and potassium permanganate, the Ro values were obtained; the plot of log 
[PAM] versus log Ro gives straight line with slope value equal to one. This confirms 
the first order dependence of Ro on [PAM]. 
The plots of absorption versus time and log absorbance versus time were 
obtained and are represented in (Fig. 2.9.1-2.9.8 and Fig. 2.10.1-2.10.6) for 
paracetamol and potassium permanganate respectively, recorded at various time 
intervals. Since the reactions are carried out under pseudo-first order condition for 
different concentration of paracetamol and potassium permanganate. The values are 
obtained for rate of reaction and these are plotted against [Paracetamol] and 
[KMn04]. The constant values are obtained for specific rate constant k. These values 
are calculated from the first order integrated rate equation that confirmed the first 
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2.5 Values for reaction rate and specific rate constant for kinetics of 
degradation of paracetamol by potassium permanganate in neutral medium by 
varying [KMn04]. 
Table 2.5.1: [Paracetamol] 
Temp = 35 °C. 
0.5x10"^ mol.dm"^ [KMn04] = 0.3x10"^ mol.dm"\ 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.392 
0.380 
0.369 
0.360 
0.352 
0.346 
0.340 
0.335 
0.331 
0.326 
0.322 
0.317 
0.314 
0.310 
0.308 
-d[A]/dt=kc"xlO-^ 
0.60 
0.58 
0.53 
0.50 
0.46 
0.43 
0.41 
0.38 
0.37 
0.35 
0.34 
0.33 
0.32 
0.30 
kxlO"^ (min"') 
1.5 
1.5 
1.4 
1.3 
1.2 
1.1 
1.1 
1.0 
1.0 
0.9 
0.9 
0.9 
0.9 
0.9 
Table 2.5.2: [Paracetamol] = 0.5x10"^ mol.dm"', [KMn04] = 0.4x10"' mol.dm 
Temp = 35 C. 
Time (min) Absorbance -d[A]/dt=kc"xlO ^ k xlO ^ (min"') 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
0.602 
0.592 
0.581 
0.572 
0.565 
0.557 
0.550 
0.554 
0.539 
0.534 
0.529 
0.525 
0.521 
0.516 
0.512 
5.00 
5.50 
5.00 
4.62 
4.50 
4.33 
3.43 
3.94 
3.78 
3.65 
3.50 
3.37 
3.31 
3.21 
8.3 
8.8 
8.5 
7.9 
7.7 
7.5 
7.2 
6.9 
6.7 
6.5 
6.2 
6.0 
5.9 
5.8 
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-3 ,-3 Table 2.5.3: [Paracetamol] = 0.5x10"'' mol.dm"'. [KMn04] = 0.5x10"' mol.dm"', 
Temp = 35 C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.811 
0.799 
0.789 
0.778 
0.770 
0.763 
0.755 
0.749 
0.744 
0.738 
0.733 
0.728 
0.727 
0.722 
0.719 
Table 2.5.4: [Paracetamol] = 0.5x10"^ 
Temp - 35 C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.064 
1.059 
1.047 
1.038 
1.028 
1.022 
1.013 
1.007 
1.001 
0.996 
0.989 
0.985 
0.979 
0.976 
0.971 
-d[A]/dt=kc' 
6.00 
5.50 
5.50 
5.12 
4.80 
4.67 
4.43 
4.19 
4.06 
3.90 
3.77 
3.50 
3.42 
3.29 
x^iO"^  
mol.dm"^ [KMn04] = 
-d(A]/dt=kc"; 
2.50 
4.25 
4.33 
4.50 
4.20 
4.25 
4.07 
3.94 
3.78 
3.75 
3.59 
3.54 
3.38 
3.32 
<10^ 
k xlO ^ (min ') 
7.4 
6.9 
6.9 
6.5 
6.1 
5.9 
5.7 
5.4 
5.2 
5.1 
4.9 
4.6 
4.5 
4.3 
0.6x10'^ mol.dm"^ 
kxiO^(min') 
2.3 
4.0 
4.1 
4.3 
4.0 
4.1 
3.9 
3.8 
3.6 
3.6 
3.5 
3.4 
.3.3 
3.2 
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Table 2.5.5: [Paracetamol] = 0.5x10"^ mol.dm"^ [KMn04] = 0.7x10"-^  mol.dm"^ 
Temp = 35 C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.172 
1.162 
1.150 
1.138 
1.129 
1.121 
1.114 
1.108 
1.100 
1.094 
1.091 
1.084 
1.078 
1.074 
1.069 
-d[A]/dt=kc"xlO"^ 
5.00 
5.50 
5.67 
5.37 
5.10 
4.83 
4.57 
4.50 
4.33 
4.05 
4.00 
3.92 
3.77 
3.68 
k xW^ (min ') 
4.3 
4.7 
4.9 
4.6 
4.4 
4.2 
4.0 
3.9 
3.8 
3.5 
3.5 
3.4 
J . J 
3.2 
Table 2.5.6: [Paracetamol] = 0.5x10"^ mol.dm"^ [KMn04] = 0.8x10'^ mol.dm'l 
Temp = 35''C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.418 
1.408 
1.396 
1.384 
1.378 
1.370 
1.358 
1.350 
1.343 
1.337 
1.331 
1.326 
1.320 
1.316 
1.312 
-d[A]/dt=kc"xlO ^ 
5.00 
5.50 
5.67 
5.00 
4.80 
5.00 
4.86 
4.69 
4.50 
4.35 
4.18 
4.08 
3.92 
3.79 
k xlO ^ (min^) 
3.5 
3.9 
4.0 
3.6 
3.4 
3.6 
3.5 
3.4 
3.3 
3.2 
3.0 
3.0 
3.0 
3.0 
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Table 2.5.7: [Paracetamol] = 0.5x10'^ mol.dm"\ [KMn04] = 0.9x10'^ mol.dm' 
Temp = 35 C. 
Time(min) Absorbance -d[A]/dt=kc"xlO^ kxlO^(inin') 
2 \M6 
4 1.636 5.00 3.0 
6 1.622 6.00 3.7 
8 1.610 6.00 3.7 
10 1.599 5.87 3.6 
12 1.590 5.60 3.5 
14 1.582 5.33 3.3 
16 1.575 5.07 3.2 
18 1.568 4.87 3.2 
20 1.562 4.67 2.9 
22 1.556 4.50 2.8 
24 1.550 4.36 2.7 
26 1.544 4.25 2.7 
28 1.541 4.04 2.5 
30 1.535 3.96 2.5 
Table 2.5.8: [Paracetamol] = 0.5x10"^ mol.dm'^ [KMn04] = 1.0x10"^  mol.dm 
Temp = 35 C. 
3 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.754 
1.750 
1.735 
1.723 
1.712 
1.703 
1.695 
1.687 
1.680 
1.673 
1.667 
1.662 
1.658 
1.653 
1.649 
-d[A]/dt=kc"xlO"^ 
2.00 
4.75 
5.17 
5.25 
5.10 
4.92 
4.79 
4.62 
4.50 
4.35 
4.18 
4.00 
3.88 
3.75 
kxlO ^ (min"') 
1.1 
2.7 
2.9 
3.0 
2.9 
2.8 
2.7 
2.6 
2.6 
2.5 
2.4 
2.3 
2.2 
2.2 
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2.6 Values for reaction rate and specific rate constant for kinetics of 
degradation of paracetamol by KMn04 in neutral medium by varying 
[Paracetamol]. 
Table 2,6.1: [KMn04] = 0.6x10"^ mol.dm'l [Paracetamol] = 0.4x10"'' mol.dm"^ 
Temp = 35 C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.047 
1.031 
1.022 
1.014 
1.008 
1.002 
0.997 
0.993 
0.987 
0.983 
0.980 
0.976 
0.972 
0.969 
0.966 
-d[A]/dt=kc"xiO-^ 
8.00 
6.25 
5.50 
4.87 
4.50 
4.17 
3.86 
3.75 
3.55 
3.35 
3.23 
3.12 
3.00 
2.89 
kxlO"' (min') 
7.7 
6.0 
5.3 
4.7 
4.3 
4.1 
3.8 
3.7 
3.5 
J . J 
3.1 
3.0 
2.9 
2.8 
Table 2.6.2: [KMn04] = 0.6x10"^ mol.dm"^ [Paracetamol] = 0.5x10-^ mol.dm'\ 
Temp = 35°C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.070 
1.065 
1.053 
1.042 
1.034 
1.026 
1.020 
1.013 
1.008 
1.001 
0.996 
0.991 
0.987 
0.983 
0.978 
-d[A]/dt=kc"xlO-^ 
2.50 
4.25 
4.67 
4.50 
4.40 
4.17 
4.07 
3.87 
3.83 
3.73 
3.59 
3.46 
3.35 
3.29 
k xio ^ (min ') 
2.3 
4.0 
4.4 
4.2 
4.2 
4.0 
3.9 
3.7 
3.7 
3.6 
3.5 
3.4 
3.3 
3.2 
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Table 2.6.3: [KMn04] = 0.6x10"^ mol.dm'^ [Paracetamol] = 0.6x10"^ mol.dm"\ 
Temp = 35 '^ C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.977 
0.973 
0.958 
0.945 
0.935 
0.926 
0.918 
0.910 
0.902 
0.895 
0.890 
0.884 
0.878 
0.873 
0.869 
-d[A]/dt=kc"xlO"^ 
2.00 
4.75 
5.33 
5.25 
5.10 
4.92 
4.79 
4.69 
4.56 
4.35 
4.23 
4.13 
4.00 
3.86 
kxlO^(min') 
2.0 
4.9 
5.5 
5.5 
5.3 
5.2 
5.1 
5.0 
4.7 
4.5 
4.4 
4.5 
4.3 
4.2 
Table 2.6.4: [KMn04] = 0.6x10"^ mol.dm•^ [Paracetamol] = 0.7x10"'' mol.dm"\ 
Temp = 35 ^C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.935 
0.914 
0.898 
0.885 
0.874 
0.864 
0.856 
0.848 
0.841 
0.834 
0.828 
0.822 
0.817 
0.813 
0.807 
-d[A]/dt=kc"x 0"^  
10.5 
9.25 
8.33 
7.63 
7.10 
6.58 
6.21 
5.87 
5.61 
5.35 
5.14 
4.92 
4.69 
4.57 
kxlO ^ (min ') 
11.3 
10.9 
9.1 
8.4 
7.8 
7.4 
6.9 
6.6 
6.4 
6.1 
5.9 
5.6 
5.8 
5.3 
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Table 2.6.5: [KMn04] = 0.6x10"^ mol.dm"^ [Paracetamol] - 0.9x10"'' mol.dm"^ 
Temp = 35 C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.738 
0.730 
0.712 
0.695 
0.680 
0.669 
0.658 
0.648 
0.639 
0.632 
0.624 
0.617 
0.611 
0.605 
0.599 
-d[A]/dt=kc"xlO ^ 
4.00 
6.50 
7.17 
7.25 
6.90 
6.67 
6.43 
6.19 
5.89 
5.70 
5.50 
5.29 
5.11 
4.96 
kxlO"* (min') 
0.54 
0.89 
1.00 
1.02 
0.98 
0.96 
0.93 
0.90 
0.96 
0.83 
0.81 
0.78 
0.76 
0.74 
Table 2.6.6: 
Temp = 35 C. 
Time (min 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
[KMn04] 
) 
= 0.6x10'^ 
Absorbance 
0.632 
0.590 
0.569 
0.552 
0.539 
0.527 
0.517 
0.508 
0.499 
0.492 
0.485 
0.480 
0.474 
0.468 
0.463 
mol.dm" ,^ [Paracetamol] = 
-d[A]/dt=kc' 
21.0 
15.7 
13.3 
11.6 
10.5 
9.58 
8.86 
8.31 
7.78 
7.35 
6.91 
6.58 
6.31 
6.04 
'XIQ-^ 
l.Ox 
k; 
10"^  mol.dm'l 
<10 ^  (min') 
3.4 
2.6 
2.2 
1.9 
1.8 
1.6 
1.3 
1.4 
1.3 
1.3 
1.2 
1.2 
1.1 
l.I 
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order depeiadence on both [Paracetamol] and [KMn04]. It can be seen from the Table 
2.5.1-2.5.8 and Table 2.6.1-2.6.6 respectively. 
log ([A]o / [A]) = kt/2.303 (first order) 
In this equation, [A] is the concentration of A at some time, t. after the reaction 
begins, and [A] o is the initial concentration of A. (The logarithm is to the base 10. *) 
If we solve this relationship for k we get 
k = log ([A] o / [A]) X 2.303/t (first order) 
There exist a similarity of k values obtained by first order integrated kinetics equation, 
both for [Paracetamol] and [KMn04]. 
2.3.5 Effect of temperature on the reaction rate 
The effect of change in temperature was examined in the temperature range 
25-55 "^ C. As the temperature increases, the rate of the reaction should increase 
according to Arrhenius equation. For the effect of change in temperature on reaction 
rate, the Arrhenius equation was used to calculate the various activation parameters of 
the reaction products; 
In k- In A - Ea/RT 
The rate constant k of the slowest step was obtained from the slope of log Abs 
versus time plots (Figure 2.11) at four different temperatures with respect to different 
concentration of [Paracetamol] and [MnO^] (Table 2.7). The energy of activation 
corresponding to different rate constants obtained at varying temperatures was 
calculated from the Arrhenius plot of log k versus 1/T (Fig. 2.12). It is found that a 
plot of In k against 1/T gives a straight line with negative slope. This further confirms 
the first order dependence on the reactants. This also helped to deduce the kinetic rate 
expression for the oxidation of the paracetamol by potassium permanganate. 
Activation energy (Ea) can be calculated from the slope (-Ea/2.303R) and A 
(pre-exponential factor) from the intercept of the Arrhenius curve and found to be 
23.9 kJ mol"' and 1.46091, respectively. The other activation parameters such as 
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Table 2.7: log Absorbance versus Time at different temperatures. Reaction 
Conditions: [Paracetamol] = 0.4x10'Vol.dm"^ [MnO;] = 0.6x10'^ mol.dm"'. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
log A (25 "C) 
0.008 
0.004 
0.000 
-0.002 
-0.002 
-0.013 
-0.006 
-0.008 
-0.008 
-0.000 
-0.013 
-0.000 
-0.015 
-0.015 
-0.015 
log A (35 "C) 
0.019 
0.013 
0.009 
0.006 
0.003 
0.000 
-0.001 
-0.003 
-0.005 
-0.007 
-0.008 
-0.010 
-0.012 
-0.013 
-0.015 
log A (45 "C) 
0.041 
0.031 
0.026 
0.021 
0.017 
0.013 
0.010 
0.006 
0.003 
0.001 
-0.000 
-0.002 
-0.005 
-0.007 
-0.008 
log A (55 °C) 
0.037 
0.028 
0.020 
0.013 
0.007 
0.003 
-0.000 
-0.004 
-0.007 
-0.010 
-0.011 
-0.013 
-0.016 
-0.018 
-0.019 
Table 2.8: Value of k (rate constant) calculated from slopes of log absorbance 
versus time plots multiplied by 2.303. Reaction Conditions: [Paracetamol] = 0.4x10"* 
-3 
mol.dm", [MnO;] = 0.6x10'" mol.dm"'. 
Temp. (K) 1/T Slope logk 
298 0.00335 
308 0.00324 
318 0.00314 
328 0.00304 
Activation parameters: 
Ea =23.9kJmor' 
AH* = 21.4kJmo]"' 
AS* = -225 JK-'moi"' 
AG" = 88.4 kJmor' 
-0.00079 
-0.00110 
-0.00161 
-0.00186 
0.0018113 
0.0025333 
0.0037078 
0.0042836 
-2.74200 
-2.59631 
-2.43088 
-2.36819 
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enthalpy, entropy and free energy of activation of the reaction product were calculated 
using eyring equation: 
, k , k, ISS* AH' 1 
log - = log — + 
T h 2.303^ 2.303i? T 
kb = Boltzmann's constant (1.38106x10'" J,K'') 
T = absolute temperature in degrees Kelvin (K) 
h = Plank constant (6.626x10"^"* J s) 
R = Universal Gas Constant = 8.314x10"^ K J 
AS = activation entropy (J K" mol' ) 
AH = activation enthalpy (k J mol") 
AG = free activation enthalpy (k J mol' ) 
The plot of log k/T versus 1/T (Fig. 2.13) was linear with correlation 
coefficient of 0.9841. AH* was evaluated from the slope (-AH''/2.303R) and AS** from 
the intercept [log (kb/h) + AS*'/2.303R] of the compiled Eyring plot. The values of 
AH** and AS** were found to be 21.4 kJ mol'' and -225 J K"' mol'' respectively (Table 
2.8). The Gibbs free energy of activation was determined at 298 K and found to be 
88.4kJ mol"' by using , AG*= AH**- TAS** 
The negative entropy of activation is characteristic of the existence of compact 
transition state. AS* suggests the formation of an activated complex with a reduction 
in the degrees of freedom of molecules. The fairly high positive value of enthalpy 
(AH*) indicates that the transition state is highly solvated. A meaningful mechanistic 
explanation of the apparent values of AS* and AH* is not possible because the kobs 
does not represent a single elementary kinetic step. 
2.3.6 Electronic spectra 
The UV-visible spectra of the reacting solution over the time are shown in 
(Fig. 2.14). The spectra show two absorption peaks at 400nm and 525nm at beginning 
of the reaction. It shows a continuous decrease in the absorbance at 525nm which 
indicates that [MnO^] is used up to oxidize the paracetamol in the reaction. The 
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Fig. 2.13: Eyring plot: log k/T versus 1/T for AH* and AS*. 
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Fig. 2.14: Spectral changes occurring during the oxidation of paracetamol by 
permanganate at initial paracetamol concentration of 0.4x10"^ mol.dm"^ 
and KMn04 concentration of 0.6x10'^ mol.dm"^ at 35 °C, the top curve 
for t = 0 min and the bottom for t = 90 min. 
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decrease in absorbance with the course of reaction follows first-order fashion. Further, 
there is a slight decrease in absorbance at 600nm and 700nm suggest that Mn04 " and 
Mn04"'' apparently does not form as reaction products. At a wavelength 450nm, the 
spectrum of the initial solution has the lowest absorbance and MnO^ is almost 
transparent to source light. The increase of absorbance at 450nm with time indicates 
the formation of a decomposition product of MnO^. 
2.3.7 Mechanism 
Permanganate ion, MnO 4, is a powerful oxidant, as it exhibits many oxidation 
states; the oxidation was indicated by the appearance of brown color in the reaction 
mixture after the addition of oxidant. Oxidation of paracetamol was found to take 
place very quickly as observed by color change of the reaction mixture from violet to 
red color and then to orange color, as the reaction proceeds, slowly yellow turbidity 
develops, after keeping for a long time the solution turns to colorless resulting in a 
brown precipitate. This suggests that the product formed might have undergone 
further oxidation resulting in a lower oxidation state of manganese, Mn (IV). There is 
a continuous decrease in absorbance during the course of absorbance which indicates 
degradation in the concentration of paracetamol. The degradation pathway of 
paracetamol is shown in (scheme 1). 
Many researchers [24, 26] have proposed similar mechanism for one step, one 
electron transfer; the adsorption of paracetamol on the surface of the colloidal MnOa 
can be seen from (Eq.5 in Scheme 2). The hydrogen bonding between the -OH group 
of paracetamol and MnOi is responsible for the formation of complex C. It has been 
found [27-29] that C decomposes by a one step, one-electron oxidation-reduction 
mechanism to Mn (III) and other products (Eq.5 in Scheme 2). Mn (III) is a strong 
oxidant and is unstable with respect to disproportionation in the presence of large 
amount of paracetamol; it immediately gets converted into stable products (Eq.8 in 
Scheme 2). 
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2.3.8 Product Analysis 
After complete degradation of paracetamol, which was confirmed from no 
change in absorbance after 90 min., the whole reaction mixture (PAM==2xlO" mol. 
dm"^  i.e. 0.120 gm in 50 ml distilled water: KMnO4=10xl0"^mol.dm"^ i.e. 0.400 gm in 
25 ml distilled water) was extracted with 50 ml chloroform. The chloroform layer was 
washed with 3x50 ml distilled water. Chloroform was evaporated and the product 
obtained was crystallized. The product obtained was compared with benzoquinone by 
spot method [30]. Melting point of these crystals was similar to that of benzoquinone 
(m.p. = 114-116 °C). Sultan also suggested similar products by using different oxidant 
[31]. Free radical formation was confirmed following the literature method [32]. 
Product formation was further supported by detection of ammonium ions in solution 
that was verified by spot test [30]. 
The degraded solution was mixed with a drop of concentrated sodium hydroxide solution on a watch 
glass and than a micro drop of the resulting solution was transfer to the drop reaction paper and a 
drop of Nesseler's reagent was added An orange red stain was produced which confirms the 
ammonium ions 
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CHAPTER-III 
Kinetics and Mechanism of Oxidative 
Degradation of Paracetamol by Potassium 
Dichromate in Acidic Medium 
3.1 INTRODUCTION 
Paracetamol (A -^acetyl-;?-aminophenol) (PAM) is well known for its analgesic 
and antipyretic action. It is the most widely used medicine worldwide for the relief of 
pain associated with headache, backache, and postoperation. On the other hand, when 
consumed in overdose, it may cause severe hepatic toxicity or death. Several 
spectroscopic methods for its determination based on the oxidation have been 
reported [1-3]. There is hardly any work with regard to the kinetics of oxidation of 
this drug in literature except for two cases [4-5]. Kinetics of oxidation of paracetamol 
by alkaline diperiodatoargentate(lll) has also been studied [6]. The oxidation of 
paracetamol is of interest in view of the importance of understanding the mechanisms 
of metabolic conversion of paracetamol in biological systems. The kinetics and 
mechanism of oxidation of paracetamol by chromium (VI) has been well studied [7], 
and chromic acid as one of the most versatile of the available oxidizing agents 
reacting with diverse kinds of substrates. Development of newer chromium (VI) 
reagents [8-11] for the oxidation of organic substrates continues to be a subject of 
interest. 
Our investigations provide a detailed process-level understanding of the 
oxidative degradation of paracetamol by dichromate. The specific objective are (a) to 
examine reaction order, degradation rate and kinetic behavior of paracetamol in 
reaction with dichromate. (b) to demonstrate the extent of degradation, and (c) 
Investigation of the reaction at different temperatures which allowed the 
determination of the activation parameters with respect to the slowest step. 
3.2 EXPERIMENT 
3.2.1 Instruments 
Thermo spectronic Genesis 20 UV-visible spectrophotometer with matched 
quartz cells was used to measure absorbance. A high precision water bath was used to 
control the heating temperature for color development. 
3.2.2 Chemicals and reagents 
All reagents and chemicals used were of analytical grade. Potassium 
dichromate (GR Grade, Merck.) was used as an oxidant. The drug, paracetamol 
(Glaxo) was used in the study. Deionized water was used throughout the experiment. 
3.2.3 Preparation of KzCr:©? acidic solution 
Potassium dichromate solution is freshly prepared. K2Cr207 (0.0735 gm) was 
quantitatively transferred into a 25 ml standard flask and completed to volume with 
the stock solution of H2SO4 (0.1 mol.dm"^ ) i.e makeup with deionized water. The 
solution of K2Cr207 was stored in a dark glass bottle. 
3.2.4 Preparation of sample solution of pharmaceutical tablet 
The tablets were powdered and weighed. A small quantity (0.0377 gm) was 
transferred into 25 ml standard flask and dissolved in 15 ml of water. The contents of 
the flask were swirled for 30 min, and then completed to mark with water. The 
solution was filtered through a Whatmann no. 42 filter paper (Whatmann International 
Limited, Kent, UK). It was further diluted according to the need and subjected to the 
degradation procedure for paracetamol. 
3.2.5 Kinetic Approach 
The oxidation of paracetamol by dichromate was studied under pseudo-first 
order conditions. The spectrophotometric kinetic studies were performed on the basis 
of the absorbance (optical density) noted at X^ax (wavelength) as a function of time. 
These reading were conveniently made with a Genesis-20 spectrophotometer for 
relatively slow reactions. The sample was withdrawn from the thermo stated reaction 
mixture for measurement. The reaction was initiated by mixing the required quantities 
of paracetamol and dichromate at desired temperature in the range (35-65 "C). The 
progress of the reaction was observed spectrophotometrically by pipetting 
out aliquots at different time intervals and measuring the change in the absorbance 
at its Amax 345 nm. 
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In order to obtain spectroscopic characteristics of intermediates or products 
formed during the reactions, the reaction solution was successively scanned by a UV-
visible spectrophotometer {UV mini 1240 Shimadzu). The solution was sampled in 
time and successively scanned at wavelength 200 to 500 nm to observe the changes in 
spectrum over the course of reaction. 
RESULT AND DISCUSSION 
3.3.1 Dependence on [Paracetamol] and [Dichromate] 
In order to investigate the kinetics of paracetamol-dichromate reaction, a 
series of experiments were carried out under pseudo-first order conditions. 
[Paracetamol] is varied from 0.1x10"^  to 1.0x10"^  mol.dm"^  at constant [Dichromate] 
0.5x10"^  mol.dm'^  (Table 3.1) shows that kobs increases with increase in concentration 
of paracetamol. The kobs [Paracetamol] plot is linear passing through the origin 
indicating first-order dependence on [Paracetamol] Fig. 3.1 depicts the dependence of 
kobs on [Paracetamol] at constant [Dichromate]. The pseudo-first order rate constants 
(kobs, min'') were calculated from the slopes of plots of log Abs vs time Fig. 3.2.; 
[Dichromate] varied from 0.2x10"^  to 0.75x10"^  mol.dm"^ , at constant [Paracetamol] 
1.0x10'" mol.dm'^ ). It was observed that as the initial [Dichromate] increased, the 
values of k^ bs decreased are summarized in (Table 3.2). The abnormal behavior 
probably was due to possible flocculation of colloidal particles. 
3.3.2 Oxidation kinetics 
Kinetic experiments of oxidation of paracetamol with dichromate were 
conducted at a constant temperature of 35 °C under dark conditions. The paracetamol 
degradation curves are shown in Figs. 3.3 and 3.4. In Fig. 3.3 the initial dichromate 
concentration was held constant at 0.5x10'^  mol.dm"^  and the initial paracetamol 
concentration was varied (0.4 to 0.7)xl0"^ mol.dm"''. Fig. 3.4 shows the degradation of 
paracetamol at four different initial dichromate concentrations (0.1, 0.2, 0.4 and 
0.65)xl0'^ mol.dm"' with a constant initial paracetamol concentration of 1.0x10'^  
mol.dm"^ . It is evident from Fig. 3.3 and Fig. 3.4 that paracetamol degraded faster at 
higher concentration of paracetamol and dichromate. As can be expected, the plots of 
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Table 3.1: Variation of pseudo-first-order rate constant (kobs) for the oxidation of 
paracetamol by dichromate at 345 nm, [Dichromate] = 0.5xlO"^mol.dm"\ Temp = 35 
V. 
Drug lO-^mol.dm-^ 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1.0 
k<,bsXlO"^niin 
1.56 ±0.002* 
2.64 ± 0.003 
3.86 ±0.004 
5.55 ± 0.005 
7.11 ±0.005 
8.10±0.006 
9.58 ±0.007 
10.8 ±0.009 
12.4 ±0.009 
13.4 ±0.011 
Paracetamol 
b Error limits are standard deviations. 
Table 3.2: Variation of pseudo-first-order rate constant (kobs) for the oxidation of 
paracetamol by dichromate at 345 nm, [PAM] = 1 .Ox 10"^  mol.dm"^ . Temp = 35 "C. 
Oxidant Conc.xlO'^ mol.dm"^ kobsXlO'^ min"' 
Potassium dichromate 0.1 26.3±0.006'' 
0.2 21.7 ±0.008 
0.3 17.3 ±0.011 
0.4 15.2±0.10 
0.5 13.6 ±0.0011 
0.65 09.9 ±0.009 
0.7 08.4 ±0.010 
b Error limits are standard deviations. 
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concentration versus time could be fitted to an exponential curve in all cases. The 
degradation of paracetamol can be described with the following general rate equation 
r = -1/a (d[Paracetamol]/dt) = k [Paracetamol] '^  [Dichromate] - (1) 
When the concentration of [Dichromate] is in excess, Eq. (1) can be simplified as Eqs. 
(2) and (3). 
r = kobs [Paracetamol]" (2) 
kobs = k[Dichromate] ^ (3) 
where r is a reaction rate, k the rate constant, [Paracetamol] and [dichromate] 
the concentrations of paracetamol and dichromate, respectively, x and y are the 
orders of the reaction with respect to each reactant. kobs is a pseudo-order rate constant 
because [dichromate] is effectively constant during the course of experiment. By 
varying the values of [Paracetamol] and measuring reaction rate, the order x with 
respect to [Paracetamol] can be simply determined by a log-log form of Eq. (2): 
log r = log kobs + X log [PAM] (4) 
In a similar way but varying initial concentration of [Dichromate] and measuring kobs, 
the order y with respect to [Dichromate] can be obtained by a log-log form of Eq. (3): 
log kobs = log k + y log [Dichromate] (5) 
To eliminate the errors from competitive reaction that may be induced using 
integral method, the initial rate method was used to measure the rate parameters of 
reaction. At the beginning of the reaction both of paracetamol and dichromate 
concentrations are known. The paracetamol and dichromate concentrations and the 
calculated rate constants are summarized in Tables 3.3 and 3.4. The initial reaction 
rates were determined from the tangent of the paracetamol concentration-time curve 
in Fig. 3.3 and Fig. 3.4att=0. 
The two sets of kinetic experiments were designed to calculate x and y values 
for paracetamol oxidation. The first set of four experiments was conducted with initial 
paracetamol concentrations varying (0.4 to 0.7)xl0"^ mol.dm'^ The initial dichromate 
concentration was fixed at 0.5x10'^  mol.dm"^  for all experiments. The initial reaction 
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Table 3.3: Effect of [PAM] on the RQ for the oxidation of paracetamol with 
[Dichromate] = 0.5x10-^  mol.dm'\ Temp = 35 °C. 
[PAMJxlO'^ moI.dm'^  roxlO^moI.dm^min' kobsXlO'^ min 
0.4 0.76 0.5550 
0.5 0.95 0.7116 
0.6 1.07 0.8106 
0.7 1.25 0.9580 
Table 3.4: Effect of [Dichromate] on the Ro for the oxidation of paracetamol with 
[Dichromate], [PAM] = 1.0xl0"^mol.dm"\ Temp = 35°C. 
[OxidantjxlO"^ mol.dm'^  roXlO"''mol.dm"^ min"') kobsXlO'^ min' 
0.1 0.61 2.6369 
0.2 0.94 2.1694 
0.4 1.46 1.5176 
0.65 1.64 0.9926 
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Fig. 3.5: Plot of initial rates versus the initial concentration of paracetamol at 
constant initial Dichromate concentration of 0.5x10' mo l.dm-^  at 35 "C 
(ro, initial rate of reaction in mol.dm'^ ; paracetamolo, initial 
paracetamol concentration in mol.dm" )^. 
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Fig. 3.6: Plot of kobs versus initial dichromate concentration at constant initial 
paracetamol concentration of l.OxlO'^ mol.dm"^ at 35 °C (k, pseudo-
first-order rate constant in min"'; Dichromateo, initial Dichromate 
concentration in mol.dm" )^. 
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rates were determined as the tangent to the paracetamol concentration-time curve. The 
rate at which paracetamol is degraded can be simply measured when the other 
reactant, dichromate, is held essentially constant throughout the experiment. In Fig. 
3.5 the log of initial rates versus the log of the initial paracetamol is shown. The slope 
of the calculated linear regression gave the rate order x = 0.86099 (~1), indicating a 
first order reaction with respect to paracetamol concentration. 
In the second set of four similar experiments, the initial concentration of 
pavacetamol was feed at 1.0x10"^  mol.dm'^ and paracetamol was reacted with 
dichromate ranging from 0.1x10"^ to 0.65xI0'^mol.dm"^. Fig. 3.6 shows the log of the 
pseudo-first-order rate constant (kobs) versus the log of initial dichromate 
concentration. The slope of regression line is y = 0.90114 (~1), indicating that the 
reaction is also near first-order with respect to the dichromate concentration. 
From Fig. 3.6, the rate constant for the overall reaction can be calculated. The 
y-intercep of the gradient (-4.8122) is the antilog of the second order rate. Thus, Eq. 
(1) can be rewritten as Eq. (6). The results indicate that the overall reaction is a 
second-order reaction and first-order reaction with respect to both dichromate and 
paracetamol. 
r= 1.54x10'^  [Paracetamol][Dichromate] (6) 
The first-order reaction rate with respect to the initial paracetamol 
concentration is also confirmed in Fig. 3.7. where the log of Paracetamol/ 
Paracetamolo versus time of four different initial paracetamol concentrations is 
shown. The slope of the linear regression shows a linear relationship, indicating first 
order with respect to the paracetamol concentration. Similarly, at different initial 
dichromate concentrations, the log of dichromate/dichromatCo versus time Fig. 3.8 
also shows a linear relationship, demonstrating first order with respect to the 
paracetamol concentration as well. 
3.3.3 Chemical oxidation of paracetamol and dichromate 
To obtain the different kinetic parameters for degradation of PAM and 
dichromate and to get a rate expression (RQ) for oxidation of PAM with potassium 
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3.5 Values for reaction rate and specific rate constant for kinetics of 
degradation of paracetamol by potassium dichromate in acidic medium by 
varying [PAM] 
Table 3.5.1: [Dichromate] = 0.5x10"^  mol.dm"\ [PAM] = 0.4x10"^  mol.dm"\ Temp 
= 45 "C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.338 
1.348 
1.323 
1.304 
1.283 
1.268 
1.253 
1.242 
1.236 
1.224 
1.219 
1.215 
1.206 
1.204 
1.196 
-d[A]/dt=kc"xIO-^ 
5.00 
3.75 
5.66 
6.87 
7.00 
7.08 
6.86 
6.37 
6.33 
5.95 
5.59 
5.50 
5.15 
5.07 
kxlO-^(min'') 
-0.37 
0.28 
0.43 
0.52 
0.54 
0.55 
0.53 
0.49 
0.49 
0.47 
0.44 
0.43 
0.41 
0.40 
Table 3.5.2: [Dichromate] = 0.5x10"^  mol.dm"\ [PAM] = 0.5x10"^  mol.dm"^ Temp 
= 45°C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.383 
1.370 
1.339 
1.314 
1.292 
1.267 
1.253 
1.239 
1.228 
1.216 
1.205 
1.199 
1.197 
1.187 
1.180 
-d{A]/dt=kc"xlO-^ 
6.50 
11.0 
11.5 
11.4 
11.6 
10.8 
10.3 
9.69 
9.27 
8.90 
8.36 
7.75 
7.53 
7.25 
kxlO"^ (min') 
0.47 
0.80 
0.85 
0.85 
0.88 
0.82 
0.78 
0.74 
0.72 
0.69 
0.65 
0.60 
0.59 
0.57 
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Table 3,5.3: [Dichromate] = 0.5x10"' mol.dm" 
45 °C 
[PAM] = 0.6x10"^  mol.dm"\ Temp 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.370 
1.347 
1.309 
1.281 
1.257 
1.235 
1.216 
1.196 
1.183 
1.171 
1.160 
1.150 
1.140 
1.134 
1.130 
-d(A]/dt=kc"xiO-^ 
11.50 
15.25 
14.83 
14.12 
13.50 
12.83 
12.43 
11.69 
11.00 
10.50 
10.00 
9.58 
9.07 
8.57 
kxlO^(min"') 
0.85 
1.14 
1.12 
1.07 
1.04 
0.99 
0.97 
0.92 
0.87 
0.83 
0.79 
0.77 
0.73 
0.69 
Table 3.5.4: [Dichromate] = 0.5x10"^  mol.dm'\ [PAM] = 0.8x10"' mol.dm", Temp 
= 45°C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.364 
1.330 
1.281 
1.237 
1.204 
1.176 
1.146 
1.125 
1.106 
1.089 
1.073 
1.061 
1.050 
1.041 
1.031 
-d(AI/dt=kc"xlO-^ 
17.00 
20.70 
21.17 
20.00 
18.80 
18.17 
17.07 
16.12 
15.28 
14.55 
13.77 
13.08 
12.42 
11.89 
kxlO ^ (min"') 
1.3 
1.6 
1.6 
1.6 
1.5 
1.4 
1.4 
1.3 
1.2 
1.2 
1.1 
1.1 
1.0 
1.0 
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Table 3.5.5: 
= 45°C. 
[Dichromate] = 0.5x10"^  moI.dm•^ [PAM] = 0.9x10"^  mol.dm"^ Temp 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.358 
1.322 
1.266 
1.221 
1.179 
1.147 
1.120 
1.096 
1.075 
1.057 
1.038 
1.022 
1.009 
0.997 
0.986 
-d(A]/dt=kc"xio-^ 
18.00 
23.00 
22.83 
22.37 
21.10 
19.83 
18.71 
17.69 
16.72 
16.00 
15.27 
14.54 
13.88 
13.28 
kxlO"^(min"') 
1.3 
1.7 
1.8 
1.8 
1.7 
1.6 
1.5 
1.5 
1.4 
1.3 
1.3 
1.2 
1.2 
l.I 
Table 3.5.6: 
= 45°C. 
[Dichromate] = 0.5x10'^  moi.dm"\ [PAM] = 1.0x10"^  mol.dm"', Temp 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.268 
1.231 
1.158 
1.099 
1.056 
1.014 
1.000 
0.949 
0.931 
0.913 
0.890 
0.873 
0.866 
0.859 
0.847 
-d[A]/dt=kc"xiO-^ 
18.50 
27.50 
28.10 
26.50 
25.40 
22.33 
22.78 
21.06 
19.72 
18.90 
17.95 
16.75 
15.73 
15.03 
kxlO"^ (min ') 
1.5 
2.3 
2.4 
2.3 
2.2 
2.0 
2.1 
1.9 
1.8 
1.8 
1.7 
1.6 
1.5 
1.4 
11 
3.6 Values for reaction rate and specific rate constant for kinetics of 
degradation of paracetamol by k2Cr207 in neutral medium by varying 
[Dichromate]. 
Table 3.6.1 : 
= 45°C. 
[PAM] = 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
1.0x10"^  mol.dm"\ 
Absorbance 
0.294 
0.273 
0.252 
0.237 
0.220 
0.207 
0.194 
0.181 
0.173 
0.164 
0.155 
0.145 
0.134 
0.130 
0.123 
[Dichromate] 
-d(A]/dt=kc" 
10.5 
10.5 
9.50 
9.25 
8.70 
8.33 
8.07 
7.56 
7.22 
6.95 
6.77 
6.67 
6.31 
6.10 
= 0.1x10" 
xlO^ 
^ mol.dm"\ Temp 
kxlO"^(min"') 
3.7 
3.8 
3.6 
3.6 
3.5 
3.5 
3.5 
3.3 
3.2 
3.2 
3.2 
3.3 
3.1 
3.1 
Table 3.6.2: [PAM] = 
= 45°C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
1.0x10'^  mol.dm"\ 
Absorbance 
0.548 
0.516 
0.485 
0.457 
0.432 
0.412 
0.389 
0.370 
0.355 
0.338 
0.326 
0.313 
0.302 
0.290 
0.279 
[Dichromate] 
-d[A]/dt=kc" 
16.00 
15.75 
12.17 
14.50 
13.60 
13.25 
12.71 
12.06 
11.67 
11.10 
10.70 
10.25 
9.92 
9.61 
= 0.2x10-
xlO^ 
^ mol.dm"'. Temp 
kxlO^ (min*) 
3.0 
3.0 
3.0 
3.0 
2.8 
2.9 
2.8 
2.7 
2.7 
2.6 
2.5 
2.5 
2.4 
2.4 
12 
Table 3.6.3: [PAM] = 1.0x10"^  mol.dm"^ [Dichromate] = 0.5x10"^  mol.dm^ Temp 
= 45V. 
Time (min) Absorbance -d[A]/dt=kc"xlO"^ kxlO"^  (min') 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
1.339 
1.300 
1.252 
1.193 
1.153 
1.119 
1.089 
1.061 
1.040 
1.019 
1.001 
0.981 
0.969 
0.955 
0.943 
19.50 
21.70 
24.30 
23.25 
22.00 
20.80 
19.86 
18.69 
17.78 
16.90 
16.27 
15.42 
14.77 
14.10 
1.5 
1.7 
1.9 
1.9 
1.8 
1.7 
1.7 
1.6 
1.5 
1.4 
1.4 
1.3 
1.3 
1.2 
Table 3.6.4: [PAM] = 1.0x10'^  mol.dm"', [Dichromate] = 0.6x10"^  mol.dm"\ Temp 
= 45 "C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.646 
1.588 
1.514 
1.460 
1.423 
1.382 
1.352 
1.325 
1.301 
1.278 
1.261 
1.246 
1.232 
1.216 
1.210 
-d[A]/dt=kc"xlO"' 
29.00 
33.00 
31.00 
27.87 
26.40 
24.50 
22.93 
21.56 
20.44 
19.25 
18.18 
17.25 
16.54 
15.57 
kxlO"^ (min') 
1.8 
2.1 
2.0 
1.8 
1.7 
1.6 
1.5 
1.5 
1.4 
1.3 
1.3 
1.2 
1.2 
1.1 
13 
Table 3.6.5: [PAM] = 1.0x10"^  mol.dm"\[Dichroniate] = 0.65x10'^  mol.dm"^ Temp 
= 45''C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.781 
1.722 
1.664 
1.604 
1.559 
1.519 
1.489 
1.461 
1.439 
1.418 
1.402 
1.386 
1.372 
1.359 
1.348 
-d[A]/dt=kc"xiO-^ 
29.50 
29.25 
29.50 
27.75 
26.20 
24.33 
22.86 
21.37 
20.17 
18.95 
17.95 
17.04 
16.23 
15.46 
kxlO-^(niin"') 
1.7 
1.7 
1.7 
1.7 
1.6 
1.5 
1.4 
1.3 
1.3 
1.2 
1.1 
1.1 
1.0 
1.0 
Table 3.6.6: [PAM] = 1.0x10"' mol.dm'\ [Dichromate] = 0.7x10"^  mol.dm". Temp 
= 45'C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.912 
1.842 
1.779 
1.718 
1.678 
1.642 
1.609 
1.579 
1.557 
1.546 
1.524 
1.509 
1.495 
1.481 
1.476 
-dIA]/dt=kc"xlO'^ 
35.00 
33.25 
32.33 
29.25 
27.00 
25.25 
23.79 
22.19 
20.30 
19.40 
18.32 
17.37 
16.58 
15.57 
kxlO"^{min') 
1.9 
1.8 
1.8 
1.6 
1.5 
1.4 
1.4 
1.3 
1.2 
1.1 
1.1 
1.0 
0.9 
0.9 
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dichromate, a systematic approach was considered to establish the dependence of Ro 
on [PAM] and [Dichromate]. A change in concentration of paracetamol in the range 
of (1x10"^  to 1x10"^ ) moi.dm"^  was done to study the course of oxidation while 
keeping the [Dichromate] (0.5x10"^ mol.dm" )^. The plots were obtained for 
absorbance versus time and also for log abs versus time for the course of oxidation of 
paracetamol with potassium permanganate. They were almost similar and showed the 
time dependence growth of absorbance at 345 nm. For paracetamol and potassium 
dichromate, the Ro values were obtained; the plot of log [PAM] versus log R„ gives 
straight line with slope value equal to one. This confirms the first order dependence of 
Ro on [PAM]. 
The plots between absorbance versus time and log absorbance versus time 
shows that there is a decreasing trend which confirms that the reaction follows first 
order and are represented in (Fig. 3.9.1-3.9.6 and Fig. 3.10.1-3.10.6) for paracetamol 
and potassium dichromate respectively, recorded at various time intervals. Since the 
reactions are carried out under pseudo-first order condition for different concentration 
of paracetamol and potassium dichromate. The values are obtained for rate of reaction 
and these are plotted against [Paracetamol] and [Dichromate]. The constant values are 
obtained for specific rate constant k. These values are calculated from the first order 
integrated rate equation that confirmed the first order dependence on both 
[Paracetamol] and [Dichromate]. It can be seen from the Table 3.5.1-3.5.6 and Table 
3.6.1-3.6.6 respectively. 
log ([A] 0 / [A]) = kt/2.303 (first order) 
In this equation, [A] is the concentration of A at some time, t, after the reaction 
begins, and [A] o is the initial concentration of A. (The logarithm is to the base 10. *) 
If we solve this relationship for k we get 
k = log ([A] 0 / [A])x2.303/t (first order) 
There exist a similarity of k values obtained by first order integrated kinetics equation, 
both for [Paracetamol] and [Dichromate]. 
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Fig. 3.11: First order plots at different temperature's where [Paracetamol] 
1.0x10'^  mol.dm'^ and [Dichromate] = 0.3x10'-* mol.dml 
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Fig. 3.12: Arrhenius plot: log k versus 1/T for activation energy. 
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Fig. 3.13: Eyring plot: log k/T versus l/T for AH" and AS**. 
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Table 3.7: log Absorbance Vs Time at different temperatures. (Reaction 
Conditions: [Paracetamol] = 1.0x10'^  mol.dm'^ ; [Dichromate] = 
0.3x10"^  mol.dm" )^. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
log A (35 V ) 
-0.045 
-0.067 
-0.084 
-0.107 
-0.127 
-0.146 
-0.164 
-0.179 
-0.193 
-0.207 
-0.220 
-0.232 
-0.233 
-0.244 
-0.254 
log A (45 "C) 
-0.105 
-0.111 
-0.136 
-0.159 
-0.178 
-0.197 
-0.212 
-0.229 
-0.244 
-0.259 
-0.272 
-0.283 
-0.294 
-0.305 
-0.314 
log A(55 "C) 
-0.111 
-0.131 
-0.163 
-0.191 
-0.217 
-0.242 
-0.266 
-0.285 
-0.305 
-0.323 
-0.339 
-0.354 
-0.370 
-0.385 
-0.393 
log A (65 V ) 
-0.096 
-0.131 
-0.173 
-0.210 
-0.242 
-0.271 
-0.297 
-0.319 
-0.340 
-0.358 
-0.375 
-0.392 
-0.407 
-0.422 
-0.434 
Table 3.8: Value of k (rate constant) calculated from slopes of log absorbance 
versus time plots multiplied by 2.303. Reaction Conditions: [Paracetamol = 1.0x10"^  
mol.dm"^ ; [Dichromate] = 0.3x10'^  mol.dm" )^. 
Temp. (K) 1/T Slope kxlO^^min' logk 
308 0.00324 
318 0.00314 
328 0.00304 
338 0.00295 
Activation parameters: 
E, =14.1 kJmoI"' 
AH*= ll.SkJmor' 
AS* =-242JK-'mor' 
AG*=85.9kJmor' 
-0.00750 
-0.00777 
-0.01030 
-0.01183 
1.72725 
1.78943 
2.37209 
2.72444 
-1.76264 
-1.74728 
-1.62486 
-1.56472 
3.3.4 Effect of temperature on reaction rate 
For the effect of temperature on the paracetamol degradation by dichromate is 
shown in Fig. 3.11. It is obvious that the reaction rate accelerates with the increase in 
temperature and the reactions are well fit with a first-order decay model. The 
temperature influence on paracetamol oxidation by dichromate was studied at 35-65 
^C. Rate constant are used to determine the activation energy by the linearized 
Arrhenius equation (7) 
In k = In A - Ea/RT (7) 
The rate constant k of the slowest step was obtained from the slope of log Abs 
versus time plots Fig. 3.11 at four different temperatures with respect to different 
concentration of [Paracetamol] and [Dichromate] (Table 3.7). The energy of 
activation corresponding to different rate constants obtained at varying temperatures 
was calculated from the Arrhenius plot of log k versus 1/T Fig. 3.12. It is found that a 
plot of In k against 1/T gives a straight line with negative slope. This further confirms 
the first order dependence on the reactants. 
Activation energy (Ea) can be calculated from the slope (-Ea/2.303R) found to 
be 14.1 kJ mol"'. The other activation parameters such as enthalp), entropy and free 
energy of activation of the reaction product were calculated using eyring equation 
(Eq.(8)) 
, k , k, AS' AH' \ 
log - = log -^ + (8) 
T h 2.303R 2.303/? T 
The plot of log k/T versus 1/T Fig. 3.13 was linear with correlation coefficient 
of 0.9841. AH** was evaluated from the slope (-AH*'/2.303R) and AS" from the 
intercept [log (kt/h) + AS''/2.303R] of the compiled Eyring plot. The values of AH* 
and AS* were found to be 11.5 kJ mol"' and -242 J K"' mol"' respectively (Table 3.8). 
The Gibbs free energy of activafion was determined at 308 K and found to be 85.9 kJ 
mof' by using, (Eq. (9)) 
AG*= AH*- TAS* (9) 
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Fig. 3.14: Spectral changes occurring during the oxidation of paracetamol by 
dichromate: at initial paracetamol concentration of 1.0x10' 
and dichromate concentration of 0.3x10"'' mol.dm"^  at 35 °C. 
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The moderate values of AH" and AS" were both favorable for electron transfer 
processes. The value of AS" within the range for radical reaction has been ascribed to 
the nature of electron pairing and unpairing processes and to the loss of degrees of 
freedom formerly available to the reactants upon the formation of rigid transition state 
[12]. The negative value of AS* indicates that the complex is more ordered than the 
reactant [13-14]. 
3.3.5 Electronic spectra 
The changes of spectrum during the oxidation of paracetamol with dichromate 
were investigated. Fig. 3.14 shows the spectra of reacting solution over time. The 
reduction in absorbance with time in a first-order fashion indicates a decreasing 
concentration of dichromate. At a wavelength of 228 nm, the spectrum of the initial 
solution has the lowest absorbance and dichromate is almost transparent to source 
light. As expected the adsorption intensity in the region 345-350 nm (characteristic 
peak complex for dichromate) decreases gradually as the reaction proceeded, 
indicating that dichromate and paracetamol follows the course of reaction, and the 
concentrations of them decreased. Further research needs to be conducted to identify 
the intermediates produced from the oxidation of paracetamol by dichromate. 
3.3.6 Chemical background 
There has been little direct process-oriented work on the oxidation of 
paracetamol by dichromate. The oxidation of paracetamol with potassium dichromate 
was observed to be comparatively a slow process. During the reaction, the color of the 
solution remains yellow but it gets darker with respect to increase in temperature. 
There is a continuous decrease in absorbance during the course of reaction, which 
indicates degradation in the concentration of paracetamol. The degradation pathway 
of paracetamol is shown in Fig. 3.15 depicts a reaction scheme for the oxidation of 
paracetamol by dichromate. The oxidation reaction begins with the formation of 
chromate ester as the first step in the reduction of Cr (VI) [15]. Chromate ester 
undergoes oxidative decomposition in the next step (rate determining) that further 
leads to the formation of an intermediate and Cr (IV) [16]. This proposed mechanism 
is further supported by analysis of the products. 
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3.3.7 Product Analysis 
After complete degradation of paracetamol, which was confirmed from no 
change in absorbance after 90 min., the whole reaction mixture (paracetamol=2xl0"^ 
mol.dm'^  i.e. 0.120 gm in 50 ml distilled water and Dichromate=10xlO"^moI.dm"^ i.e. 
0.400 gm in 25 ml makeup with 0.1 mol.dm"^  H2SO4) was extracted with 50ml 
chloroform. The chloroform layer was washed with 3x50 ml distilled water. 
Chloroform was evaporated and the product obtained was crystallized. The product 
obtained was compared with benzoquinone by spot method [17]. Melting point of 
these crystals was similar to that of benzoquinone (m.p. =114-116 °C). Sultan, also 
suggested similar products by using different oxidant [18]. Product formation was 
further supported by detection of ammonium ions in solution that was verified by spot 
test [17]. The degraded solution was mixed with a drop of concentrated sodium 
hydroxide solution on a watch glass and than a micro drop of the resulting solution 
was transfer to the drop reaction paper and a drop of Nesseler's reagent was added. 
An orange red stain was produced which confirms the ammonium ions. 
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CHAPTER-IV 
Oxidative Degradation of Diclofenac 
sodium by Permanganate-A Kinetic and 
Mechanistic Pathway 
4.1 INTRODUCTION 
Diclofenac sodium (DS), a potential non-steroidal anti-inflammatory drug 
with pronounced analgesic properties, is used in the long-term treatment of 
rheumatoid arthritis, osteoarthritis and ankylosing spondylitis [1]. The 
pharmacological effects of this drug are thought to be related to the inhibition of the 
conversion of arachidonic acid to prostaglandins, which are the mediators of the 
inflammatory process [2-4]. The literature reports some data on chemical and 
spectroscopic characteristics of DS [5-7] and several methods for its determination. 
The most commonly used techniques are thin-layer, gas and liquid chromatography 
[8-18], generally applied for the simultaneous determination of DS and its metabolites 
in biological samples and UV-visible spectrophotometry [19-27], preferred in the 
analysis of pharmaceutical formulations. No differential scanning calorimetric (DSC) 
methods have been reported. Among the above methods, the more simple, rapid and 
sensitive are those based on the direct UV spectrophotometry, because the procedure 
involve neither complicated and time-consuming sample treatments nor the need of 
special reagents. The aim of the present study was to develop a simple, sensitive and 
rapid UV spectro-photometric method for the degradation of Diclofenac sodium by 
potassium permanganate in neutral media. 
There has been little direct process-oriented work on the oxidation of 
Diclofenac sodium by permanganate. For the DS, a lack of knowledge about the 
reaction mechanism makes it unclear whether pH will affect the degradation rates of 
Diclofenac sodium. There has been much less recent work on oxidation processes, 
even though a half-life of l-2h. Hence, the rapid absorption after oral administration 
justifies the need for a sustained release profile. Following all routes of 
administration, NSAIDs exert side effects in the lower gastrointestinal tract [28]. The 
formulator therefore has the choice of keeping a constant drug dissolution rate or 
minimizing the dissolved drug concentration, i.e. the local dose of the drug in the 
intestine. 
A specific objective of the present work was to determine an appropriate 
degradation rate for Diclofenac sodium. At low concentration, DS degradation is 
prevented, while the DS takes longer from the inner part to the intestinal juice. The 
present study is the first step towards the degradation rate, to examine reaction order, 
kinetic behavior of DS in reactions with permanganate, and also to demonstrate the 
extent of degradation. 
4.2. Experimental 
4.2.1 Apparatus 
The study was conducted using a thermo spectronic Genesis 20 UV-visible 
spectrophotometer with matched quartz cells was used to measure absorbance. A high 
precision water bath was used to control the heating temperature for color 
development. 
4.2.2 Chemicals and reagents 
Distilled, deionised and when necessary, CO2 free water was used. All 
reagents and chemicals used were of analytical grade. The drug. Diclofenac sodium 
was used in the study. DS standard solution, 0.1% (3.14x10" mol.dm') was prepared 
in deionised water. Potassium permanganate (GR Grade, Merck.) was used as an 
oxidant. A 1x10' mol.dm' KMn04 stock solution (standardized against oxalic acid 
by standard procedure [29]) was prepared in deionised water. The required 
concentrations of KMn04 solutions were prepared by diluting stock solution with 
double distilled water. However, fresh solutions were used during the experiments. 
4.2.3 Standard stock solution of Diclofenac sodium 
The average weight of a tablet (Wo) was determined by weighing 5 tablets. 
The contents of the tablets were obtained by gentle peeling of the hard coated shell. 
The tablets were finely powdered and a portion (W) of the powder (about 50 mg 
weighed accurately) was added to exactly 35 ml of water (Vf). The mixture was 
stirred about 15 min and filtered through a piece of Whatmann no. 42 filter paper. 
(Whatmann Intemafional Limited, Kent, U.K) in a 50 ml standard volumetric flask. 
The residue was washed well with deionised water for complete recovery of the drug 
and then the mixture was diluted up to the mark with deionised water. 
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4.2.4 Experimental procedure 
Kinetic runs were followed under pseudo-first order conditions. An aliquot 
(0.5 ml) of KMn04 solution was placed in 10 ml calibrated flasks. Accurate volumes 
of working soln. (3.14x10' mol.dm') of DS, over the concentration range (0.3x10' 
to 3.14x10"^) mol.dm''^, were added and the solutions were diluted to volume with 
distilled water. At a fixed time of 30 min, the absorbance was measured directly at 
525 nm against an appropriate blank. Similarly an aliquot (1 ml) of DS solution was 
placed in lOml-calibrated flask. Accurate volumes of working solution (1x10'^ 
mol.dm"'^ ) of KMn04, over the concentration range 0.1x10'^ to 1.0x10"^  mol.dm'^, 
were added and the solutions were diluted to volume with distilled water. 
The temperature influence on DS oxidation by permanganate was studied at 
25-55 "C. In order to obtain spectroscopic characteristics of intermediates or products 
formed during the reaction, the reaction solution was successively scanned by UV-
visible scan spectrophotometer (UV mini 1240 Shimadzu). The solution was sampled 
in time and successively scanned at wavelength ranging from 450 to 725 nm to 
monitor the changes in spectrum over the course of reaction. Monitoring the decrease 
in absorbance followed the course of the reaction. Regression analysis of 
experimental data to obtain the regression coefficient r and standard deviation S of 
points from the regression line was performed using a Pentium-IV personal computer. 
4.3. RESULTS AND DISCUSSION 
4.3.1 General considerations 
The limiting logarithmic method [30] was used for the determination of the 
molar ratio between KMn04 and DS in the reaction. This method depends on 
measuring the optical densities of solutions of KMn04 and DS in which the 
concentrations of the two species are varied. The ratio may be found by plotting the 
logarithms of the absorbance (A) of the two sets of solutions versus composition, one 
with constant KMn04 concentration and variable DS concentration, the other with 
constant DS and variable KMn04 concentration. The slope of the curve in case 1 
yields the number of moles of DS while that in case 2 give the number of moles of 
KMn04 and so the composition of the compound produced can be evaluated. The 
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molar ratio was found to be 3:1 for DS and KMn04 To examine the effect of 
variables, experiments were carried out under pseudo-first order conditions. 
4.3.2 Dependence on [DS] and [Permanganate] 
In order to investigate the kinetics of Diclofenac sodium-Mn04' reaction, a 
series of experiments were carried out under different experimental conditions. [DS] 
is varied from 0.3x10"^ to 3.14x10"^ mol.dm'^ at constant [Mn04"] 0.5x10"^ mol.dm'^ 
Excellent pseudo-first order behavior with respect to Mn04" was observed in these 
kinetic experiments (Table 4.1). 
Fig. 4.1 depicts the dependence of kobs on [DS] at constant [Mn04"] and 
temperature. The kobs [DS] plot is linear passing through the origin, indicating first-
order dependence on [DS]. The pseudo-first order rate constants kobs, min'' were 
calculated from the slopes of plots of log absorbance versus time. 
[Mn04"] varied from 0.2x10"^ to 0.8x10"^ mol.dm"\ at constant [DS] 3.14 
xlO"^  mol.dm"^. It was observed that as the initial [MHOA'] increased, the value of kobs 
increased (Table 4.2). At higher [Mn04"] the first-order kinefics shifts to higher order. 
It was found that the rates increased with the increase in [DS] and [Mn04"]. The 
reaction was studied at 25, 35, 45 and 55 ''C. 
4.3.3 Oxidation kinetics 
Kinetic experiments of oxidation of DS with permanganate were conducted at 
a constant temperature of 25 °C under dark conditions. The DS degradation curves are 
shown in Figs. 4.2 and 4.3. In Fig. 4.2 the initial permanganate concentration was held 
constant at 0.5x10'^mol.dm"^ and the inifial DS concentration was varied (0.9, 1.3, 1.6 
and 2.2)xl0"^ mol.dm'^ Fig. 4.3 shows the degradafion of DS at four different initial 
permanganate concentrations (0.5, 0.7, 0.9 and 1.0)xl0'^ mol.dm"'' with a constant 
initial DS concentrafion of 3.14x10'"^ mol.dm'^ It is evident from Figs. 4.2 and 4.3 
that DS degraded faster at higher concentration of DS and permanganate. As can be 
expected, the plots of concentration versus time could be fitted to an exponential 
curve in all cases. The degradation of DS can be described with the following general 
rate equation 
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Table 4.1: Variation of pseudo-first-order rate constants (kobs) for the oxidation of 
Diclofenac sodium by MnO^ at 525 nm: [MnO^ ] = 0.5xlO"Vol.dm"^ Temp = 45**C. 
Drug Conc.xloVol dm'^  kobs^^lO'^ min' 
Diclofenac sodium 0.3 ^ "^^ * ^-^^2 
2.73 ± 0.003 
b 
0.6 
0.9 
1.3 
1.6 
1.9 
2.2 
2.5 
2.8 
3.73 ±0.004 
4.54 ± 0.006 
6.49 ±0.007 
7.94 ± 0.009 
9.49 ±0.010 
11.3 ±0.014 
11.3 ±0.014 
b Error limits are standard deviations. 
Table 4.2: Variation of pseudo-first-order rate constant (kobs) for the oxidation of 
Diclofenac sodium by MnO; at 525nm, [DS] - 3.14xlO"^mol.dm"\ Temp = 45 "C. 
Oxidant Conc.xlO"^moI dm ^ kobs^lO'^min' 
Potassium permanganate 02 4.65 ± 0.007* 
0.3 6.90 ±0.011 
0.4 8.34 ±0.014 
0.5 9.97 ±0.015 
0.6 9.93 ±0.015 
0.7 10.3 ±0.017 
0.8 14.5 ±0.021 
0.9 13.5 ±0.011 
1.0 13.5±0.011 
b Error limits are standard deviations 
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[Diclofenac Sodium](mol.dm ) 
Fig. 4.1: Plot of kobs versus [Diclofenac Sodium]; Reaction conditions: 
[Permanganate] = 0.5x10'^ mol.dm"^; Temperature = 45 *^ C. 
131 
E 
"o 
c o 
c 
o c o 
o 
C/3 
Q 
0.12 
0.08-
0.04-
0.00-
-0.04-
-0.08-
-0.12-
-0.16 
0 
I—(a)y=0.02801exp(-0.00282x)R=0.9614 
»- (b) y=0.01943exp(-0.00345x) R=0.9591 
^- (c)y=0.00723exp(-0.00412x) R=0.9661 
r— (d) y=0.02002exp(-0.00477x) R=0.9339 
^ ^ 
V! 
X - A -N r . - A -
- A ^ 
—\— 
10 
—r-
15 20 
— I — 
25 
—\— 
30 
Time (min.) 
Fig. 4.2: Diclofenac sodium degradation curves at four initial DS concentrations 
= ((a) 0.9, (b) 1.3, (c) 1.6, (d) 2.2)xl0^mol.dm"^ and constant initial 
permanganate concentration = 0.5x10" mol.dm" at 45 C. 
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Fig. 4.3: Diclofenac sodium degradation curves at four initial permanganate 
concentrations = ((a) 0.5, (b) 0.7, (c) 0.9, (d) 1.0)xlO-3 mol.dm'^) and 
constant initial DS concentration = 3.14x10"^mol.dm'^ at 45 °C. 
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r = -1/a (d[DS]/dt) = k [DS]" [permanganate]'' (1) 
When the concentration of [permanganate] is in excess. Eq. (1) can be simpHfied as 
Eqs. (2) and (3). 
r = kobs[DS]'' (2) 
kobs = k [permanganate]' (3) 
where r is a reaction rate, k the rate constant, [DS] and [permanganate] the 
concentrations of DS and permanganate, respectively, x and y are the orders of the 
reaction with respect to each reactant. kobs is a pseudo-order rate constant because 
[permanganate] is effectively constant during the course of experiment. By varying 
the values of [DS] and measuring reaction rate, the order x with respect to [DS] can 
be simply determined by a log-log form of Eq. (2): 
log r = log kobs + X log [DS] (4) 
In a similar way but varying initial concentration of [permanganate] and measuring 
kobs, the order y with respect to [permanganate] can be obtained by a log-log form of 
Eq. (3): 
log kobs = log k + y log [permanganate] (5) 
To minimize the errors from competitive reaction that may be induced using 
integral method, the initial rate method was used to measure the rate parameters of 
reaction. At the beginning of the reaction both of DS and permanganate 
concentrations are known. The DS and permanganate concentrations and the 
calculated rate constants are summarized in Table 4.3 and Table 4.4. The initial 
reaction rates were determined from the tangent of the DS concentration-time curve in 
Figs. 4.2 and 4.3 at t=0. 
The two sets of kinetic experiments were designed to calculate x and y values 
for DS oxidation. The first set of four experiments was conducted with initial DS 
concentrations varying (0.9, 1.3. 1.6 and 2.2)xl0"'^  mol.dm'\ The initial permanganate 
concentration was fixed at 0.5x10'^ mol.dm"^ for all experiments. The initial reaction 
rates were determined as the tangent to the DS concentration-time curve. The rate at 
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Table 4.3: Effect of [DS] on the RQ for the oxidation of DS with [MnO;] = 
0.5x10"^ mol.dm"\ Temp = 25 "^ C. 
[DS]xlO'^mol.dm"^ roXlO^mol.dm'^ min"' R 
0.3 0.18 0.9734 
0.6 0.31 0.9558 
0.9 0.60 0.9600 
1.3 0.70 0.9547 
1.6 0.87 0.9559 
1.9 0.96 0.9724 
2.8 1.18 0.9621 
Table 4.4: Effect of [MnO^ ] on the RQ for the oxidation of Diclofenac sodium 
with [MnO-]; [DS] = 3.14xl0-^mol.dm"^ Temp = 25 °C. 
[MnO;]xlO"^mol.dm^ roXlO ^ mol.dm'^min' R 
0.2 0.25 0.9150 
0.3 0.56 0.9431 
0.4 0.89 0.9505 
0.5 1.12 0.9507 
0.6 1.56 0.9612 
0.7 1.82 0.9664 
0.8 1.99 0.9661 
0.9 2.01 0.9695 
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Fig. 4.4: 
2.7 
2.6 
y= 0 75241X - 0 82062 
R~ = 0 9994 
log Diclofenac Sodium 
Plot of initial rates versus the initial concentration of DS at constant 
initial permanganate cone, of 0.5x10'^ mol.dm'^ at 45 °C (ro, initial rate 
of reaction in mol.dm" ; diclofenac sodiumo, initial diclofenac sodium 
cone, in mol.dm'). 
to 
o 
) 
2 . 3 -
2.2 n 
2.1 -
2 . 0 -
y = 0 8226x - 0 7195 
R" = 0 9976 
/ 
1 ' 
mX 
1 
3.3 3.4 3.5 3.6 
log Permanganate 
3.7 
Fig. 4.5: Plot of k versus initial (MnOJ concentration at constant initial DS 
concentration of 3.14x10"* mol.dm'^ at 45 °C (k, pseudo-first-order rate 
constant in min"'; Permanganate^ initial Permanganate cone, in 
mol.dm"^). 
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Fig. 4.7: Plots of ln(C/Co) versus time at different initial [Mn04 ] concentrations 
and constant initial DS cone, of 3.14 xlO^ mol.dm"^ at 45 °C (Co, 
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which DS is degraded can be simply measured when the other reactant, 
permanganate, is held essentially constant throughout the experiment. In Fig. 4.4 the 
log of initial rates versus the log of the initial DS is shown. The slope of the calculated 
linear regression gave the rate order x = 0.75241 (~1), indicating that the reaction is 
also near first order reaction with respect to DS concentration. 
In the second set of four similar experiments, the initial concentration of DS 
was fixed at 3.14xl0"'*mol dm'^  and DS was reacted with permanganate ranging from 
(0.5, 0.7. 0.9 and 1.0)xlO"'' mol dm"^ Fig. 4.5 shows the log of the pseudo-first-order 
rate constant (kobs) versus the log of initial permanganate concentration. The slope of 
regression line is y = 0.8226 (~1), indicating that the reaction is also first-order with 
respect to the permanganate concentration. 
From Fig. 4.5, the rate constant for the overall reaction can be calculated. The 
y-intercept of the gradient (-0.7195) is the antilog of the second order rate. Thus. Eq. 
(1) can be rewritten as Eq. (6). The results indicate that the overall reaction is a 
second-order reaction and first-order reaction with respect to both permanganate and 
paracetamol. 
r - 0.19076 [DS] [permanganate] (6) 
The first-order reaction rate with respect to the initial DS concentration is also 
confirmed in Fig. 4.6, where the log of DS/DSQ versus time of four different initial DS 
concentrations is shown. The slope of the linear regression shows a linear 
relationship, indicating first order with respect to the DS concentration. Similarly, at 
different initial dichromate concentrations, the log of permanganate/permanganateo 
versus time Fig. 4.7 also shows a linear relafionship, demonstrating first order with 
respect to the DS concentration as well. 
4.3.4 Reaction order 
To obtain the different kinetic parameters for degradation of DS and KMn04 
and to get a rate expression (Ro) for oxidation of DS with potassium permanganate, a 
systemafic approach was considered to establish the dependence of Ro on [DS] and 
[MnO^]. A change in concentration of DS in the range of (0.3x10"^ to 3.14x10"^) 
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Fig. 4.8.1: Reaction conditions: [DS] = 0.6x10~* mol.dm'^ [Permanganate] = 0.5 
xlO"^ mol.dm'^ Temp = 45°C. 
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Fig. 4.8.3: Reaction conditions: [DS] = 1.6x10 mol.dm % [Permanganate] = 
0.5x 10"' mol.dm"', Temp = 45 T 
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Fig. 4.8.7: Effect on reaction rate; Reaction conditions: [DS] = 1.6x10" mol.dm' , 
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Fig. 4.8.9: Effect on reaction rate; Reaction conditions: [DS] = 2.2x10"' mol.dm" 
[Permanganate] = 0.5xlO•^ mol.dm"^  Temp = 45 "C 
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Fig. 4.9.1: Reaction conditions: [Permanganate] = 0.2x10"^ mol dm"^ [DS] 
3.1xlO"^mol.dm"', Temp = 45T 
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4.5 Values for reaction rate and specific rate constant for kinetics of 
degradation of DS by potassium permanganate in neutral medium by varying 
[DS]. 
Table 4.5.1: [DS] 0.6x 10"^mol.dm'^ [MnO^ ] = 0.5x 10"^  mol.dm"^ Temp = 45 °C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.095 
1.084 
1.063 
1.046 
1.009 
1.019 
1.012 
1.001 
0.997 
0.992 
0.958 
0.971 
0.975 
0.970 
0.961 
-d[A]/dt=kc"xlO ^ 
5.50 
8.00 
8.17 
10.7 
7.60 
6.92 
6.71 
6.12 
5.72 
6.85 
5.64 
5.00 
4.81 
4.79 
kxlO"^  (min ') 
0.50 
0.74 
0.76 
0.71 
0.72 
0.66 
0.64 
0.59 
0.55 
0.67 
0.55 
0.48 
0.47 
0.47 
Table 4.5.2: [DS] = 0.9x10~*mol.dm"\ [MnO;] 0.5xlO'^mol.dm"\Teinp 45 °C 
Time (min) Absorbance -d[A]/dt=kc"xlO"^  kxlO ^  (min*) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
1.095 
1.054 
1.025 
1.003 
0.987 
0.971 
0.959 
0.948 
0.940 
0.921 
0.921 
0.912 
0.908 
0.904 
0.897 
20.5 
17.5 
15.3 
13.5 
12.4 
11.3 
10.5 
9.69 
9.67 
8.70 
8.32 
7.79 
7.34 
7.07 
1.90 
1.65 
1.46 
1.29 
1.20 
1.11 
1.03 
0.95 
0.96 
0.87 
0.83 
0.78 
0.73 
0.71 
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Table 4.5.3: [DS] = 1.6x 10"^  mol.dm"\ [MnO; ] = 0.5x 10"^  mol.dm"^ Temp = 45 °C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.045 
1.006 
0.964 
0.932 
0.906 
0.888 
0.869 
0.853 
0.840 
0.830 
0.818 
0.811 
0.804 
0.795 
0.789 
-d[A]/dt=kc"xlO-^ 
19.5 
20.2 
18.8 
17.4 
15.7 
14.7 
13.7 
12.8 
11.9 
11.3 
10.6 
10.0 
9.61 
9.14 
kxlO"^  (min') 
1.90 
2.02 
1.91 
1.78 
1.63 
1.54 
1.45 
1.36 
1.28 
1.22 
1.15 
1.09 
1.05 
1.00 
Table 4.5.4: [DS] = 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
= 1.9xlO"^mol.dm"^ 
Absorbance 
1.031 
0.974 
0.923 
0.886 
0.858 
0.833 
0.815 
0.798 
0.784 
0.770 
0.760 
0.753 
0.745 
0.740 
0.735 
[MnO-] = 0.5x10' 
-d[A]/dt=kc"x 
28.5 
27.0 
24.2 
21.6 
19.8 
18.0 
16.6 
15.4 
14.5 
13.5 
12.6 
11.9 
11.2 
10.6 
"^  mol.drn 
10^ 
'-\ Temp = 45 '^C 
kxlO ^ (min ') 
2.84 
2.77 
2.53 
2.29 
2.13 
1.96 
1.83 
1.71 
1.62 
1.53 
1.43 
1.35 
1.27 
1.20 
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Table 4.5.5: [DS] - 2.2x10'^mol.dm"^ [MnO;] = 0.5x10"^mol.dm"^ Temp 45 "C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.017 
0.947 
0.899 
0.859 
0.829 
0.802 
0.787 
0.772 
0.761 
0.751 
0.743 
0.738 
0.730 
0.726 
0.721 
-d[A]/dt=kc"xlO-^ 
35.0 
29.5 
26.3 
23.5 
21.5 
19.2 
17.5 
16.0 
14.8 
13.7 
12.7 
11.9 
11.2 
10.6 
kxlO ^ (min ') 
3.56 
3.08 
2.81 
2.56 
2.38 
2.14 
1,97 
1.81 
1.68 
1.57 
1.46 
1.38 
1.29 
1.23 
Table 4.5.6: [DS] = 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
- 2.5x10'^mol.dm"l 
Absorbance 
1.000 
0.943 
0.896 
0.862 
0.837 
0.818 
0.804 
0.791 
0.782 
0.776 
0.774 
0.769 
0.767 
0.759 
0.753 
, [MnO;] = 0.5x10' 
-d[A]/dt=kc"x 
28.5 
26.0 
23.0 
20.4 
18.2 
16.3 
14.9 
13.6 
12.4 
11.3 
10.5 
09.7 
09.3 
08.8 
mol.dm 
10'^ 
l"^  Temp = 45 V 
kxlO"^ (min ') 
2.93 
2.70 
2.50 
2.20 
2.00 
1.82 
1.67 
1.54 
1.40 
1.28 
1.19 
1.10 
1.06 
1.01 
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4.6 Values for reaction rate and specific rate constant for kinetics of 
degradation of DS by KMn04 in neutral medium by varying [KMn04]. 
Table 4.6.1: [MnO;] = 0.2x10"^mol.dm"-\ [DS] = 3.1xlO"^mol.dm'\ Temp = 45 °C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.441 
0.432 
0.419 
0.411 
0.406 
0.404 
0.399 
0.399 
0.399 
0.396 
0.391 
0.380 
0.380 
0.381 
0.388 
-d[A]/dt=kc"xlO-^ 
4.50 
5.50 
5.00 
4.40 
3.70 
3.50 
3.00 
2.62 
2.50 
2.50 
2.77 
2.54 
2.31 
1.89 
kxlO'^  (min ') 
1.03 
1.28 
1.17 
1.03 
0.87 
0.83 
0.71 
0.63 
0.60 
0.60 
0.68 
0.62 
0.56 
0.46 
Table 4.8.2: [MnO^] = 0.4x10"^mol.dm"\ [DS] = 3.1xlO-^mol.dm'\ Temp = 45 °C. 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.841 
0.798 
0.759 
0.727 
0.710 
0.697 
0.689 
0.671 
0.671 
0.670 
0.664 
0.662 
0.654 
0.644 
0.636 
-d[A]/dt=kc"xlO"^ 
21.5 
20.5 
19.0 
16.4 
14.4 
12.6 
12.1 
10.6 
09.5 
8.85 
8.14 
7.79 
7.58 
7.32 
kxlO ^ (min') 
2.62 
2.56 
2.43 
2.12 
1.88 
1.66 
1.61 
1.41 
1.26 
1.18 
1.08 
1.05 
1.03 
0.99 
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Table 4.6.3: [MnO;] = 0.5x10"^mol.dm"\ [DS] = 3.1xlO"^mol.dm"\ Temp = 45 "C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
0.997 
0.953 
0.896 
0.859 
0.832 
0.811 
0.795 
0.783 
0.774 
0.767 
0.761 
0.754 
0.740 
0.740 
0.730 
-d[A]/dt=kc"xiO-^ 
22.0 
25.2 
23.0 
20.6 
18.6 
16.8 
15.3 
13.9 
12.8 
11.8 
11.0 
10.7 
9.88 
9.54 
kxlO ^ (min"') 
2.26 
2.67 
2.48 
2.26 
2.06 
1.89 
1.73 
1.58 
1.46 
1.35 
1.27 
1.24 
1.15 
1.11 
Table 4.6.4: [MnO; ] = 0.7x1 O•^mol.dm"^ [DS] = 3.1xl0"^mol.dm"^ Temp = 45 °C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.321 
1.272 
1.193 
1.139 
1.099 
1.066 
1.042 
1.025 
1.010 
0.999 
0.991 
0.986 
0.980 
0.975 
0.970 
-d[A]/dt=kc"xlO-^ 
24.5 
32.0 
30.3 
27.7 
25.5 
23.2 
21.1 
19.4 
17.9 
16.5 
15.2 
14.2 
13.3 
12.5 
kxlO"^  (min') 
1.89 
2.55 
2.47 
2.30 
2.14 
1.98 
1.81 
1.68 
1.55 
1.44 
1.33 
1.24 
1.17 
1.10 
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Table 4.6.5: [MnO;] = 0.8x10-^ mol.dm-^ [DS] = 3.1xlO-^mol.dm"^ Temp = 45 °C 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
Absorbance 
1.578 
1.458 
1.356 
1.283 
1.224 
1.177 
1.143 
1.114 
1.090 
1.069 
1.055 
1.043 
1.031 
1.024 
1.015 
-d[A]/dt=kc" xlO"' 
60.0 
55.5 
49.2 
44.2 
40.1 
36.2 
33.1 
30.5 
28.3 
26.1 
24.3 
22.8 
21.3 
20.1 
kxlO-^  (min') 
3.96 
3.79 
3.45 
3.17 
2.93 
2.69 
2.49 
2.31 
2.16 
2.01 
1.88 
1.77 
1.66 
1.58 
Table 4.6.6: [MnO,' ] - 0.9x 10"^  mol.dm'^ [DS] 3.1X10~*mol.dm"^ Temp = 45 °C 
Time (min) Absorbance -d[A]/dt=kc"xlO-^ kxlO'^ (min ') 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
1.745 
1.649 
1.549 
1.473 
1.412 
1.370 
1.334 
1.299 
1.273 
1.250 
1.231 
1.218 
1.209 
1.201 
1.192 
48.0 
49.0 
45.3 
41.6 
37.5 
34.2 
31.8 
29.5 
27.5 
25.7 
23.9 
22.3 
20.9 
19.7 
2.83 
2.98 
2.82 
2.65 
2.42 
2.24 
2.10 
1.97 
1.85 
1.74 
1.63 
1.53 
1.44 
1.36 
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mol.dm"^ was done to study the course of oxidation while keeping the [MnO^ ] (0.5 
xlO'^ mol.dm"^). The plots were obtained for absorbance versus time and also for log 
absorbance versus time for the course of oxidation of DS with potassium 
permanganate. They were almost similar and showed the time dependence growth of 
absorbance at 525 rmi. For DS and potassium permanganate, the Ro values were 
obtained; the plot of log [DS] versus log Ro gives straight line with slope value equal 
to one. This confirms the first order dependence of Ro on [DS]. 
The plots of absorption versus time and log absorbance versus time were 
obtained and are represented in Fig. 4.8.1-4.8.6 and Fig. 4.9.1-4.9.6 for DS and 
potassium permanganate respectively, recorded at various time intervals. Since the 
reactions are carried out under pseudo-first order condition for different concentration 
of DS and potassium permanganate. The values are obtained for rate of reaction and 
these are plotted against [DS] and [KMn04]. The constant values are obtained for 
specific rate constant k. These values are calculated from the first order integrated rate 
equation that confirmed the first order dependence on both [DS] and [KMn04]. It can 
be seen from the Table 4.5.1-4.5.6 and Table 4.6.1-4.6.6 respectively. 
log ([A] 0 / [A]) = kt/2.303 (first order) 
In this equation, [A] is the concentration of A at some time, t, after the reaction 
begins, and [A] o is the initial concentration of A. (The logarithm is to the base 10. *) 
If we solve this relationship for k we get 
k = log ([A] 0 / [A]) X 2.303/t (first order) 
There exist a similarity of k values obtained by first order integrated kinetics equation, 
both for [DS] and [KMn04]. 
rate - k[DS] [KMn04] 
4.3.5 Effect of temperature 
The kinetics was studied at four different temperatures under varying 
concentrations of DS and permanganate keeping other conditions constant. The rate 
constants were found to increase with increase in temperature and the reactions are 
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Fig. 4.10: First order plots at different temperature's where [Diclofenac Sodium] 
= 0.31x10"^ mol.dm"^ and [Permanganate] = 0.5x10'^ mol.dm"^. 
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Fig. 4.11: Arrhenius plot: log k versus 1/T for activation energy. 
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Table 4.7: log Absorbance Versus Time at different temperatures. Reaction 
Conditions: [DS] = 0.3x10"^ mol.dm"^ [Permanganate] = 0.5x10"^ mol.dm"^). 
Time (min) 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
log A (25 V ) 
0.055760 
0.052693 
0.050379 
0.048053 
0.046104 
0.043755 
0.042575 
0.040997 
0.040206 
0.039414 
0.038620 
0.037426 
0.036229 
0.035429 
0.034227 
log A (35 "C) 
0.093422 
0.078457 
0.074451 
0.071882 
0.070037 
0.068185 
0.066690 
0.065206 
0.063708 
0.063708 
0.062582 
0.061075 
0.061075 
0.061075 
0.059560 
log A (45 °C) 
0.068557 
0.062958 
0.058426 
0.054613 
0.051924 
0.049218 
0.047275 
0.045323 
0.043755 
0.041787 
0.040600 
0.039414 
0.038620 
0.038223 
0.037426 
log A (55 "C) 
0.065953 
0.061829 
0.054613 
0.048830 
0.044148 
0.040207 
0.035829 
0.033021 
0.030599 
0.028164 
0.026124 
0.026124 
0.024896 
0.019531 
0.019531 
Table 4.8: Effect of temperature on the oxidation of Diclofenac sodium by 
potassium permanganate in neutral medium (Reaction Conditions: [DS] = 0.3x10"^ 
mol.dm"^; [Permanganate] = 0.5x10"^ mol.dm"^) 
Temp. (K) 
298 
308 
318 
328 
1/T 
0.00335 
0.00324 
0.00314 
0.00304 
Activation parameters: 
Ea =21.1 kJmol-' 
AH* = 18.5kJmor' 
AS* =-236JK"'mol"' 
AG* = 88.9 kJmor' 
Slope 
-0.000716205 
-0.00086742 
-0.00103 
-0.00162 
kxlO^min* 
1.64942 
1.99767 
2.37209 
3.73086 
logk 
-2.782669 
-2.699480 
-2.624870 
-2.428191 
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Fig. 4.12: Eyring plot: log k/T versus 1/T for AH" and AS". 
161 
0) 
o 
•s 
^ 
200 220 240 260 280 300 320 340 
Wavelength (nm) 
Fig. 4.13: UV absorption spectra of Diclofenac sodium in aqueous solution. 
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well fit with a first-order decay model. Rate constant are used to determine the 
activation energy by the linearized Arrhenius equation 
In k = In A - Ea/RT 
The pseudo-first order rate constants (kobs, min"') were calculated fi-om the 
slopes of plot of log (absorbance) versus time multiplied by -2.303 Fig. 4.10 at four 
different temperatures with respect to different concentration of [DS] and [Mn04"] 
(Table 4.7).The energy of activation corresponding to different rate constants obtained 
at varying temperatures was calculated from the Arrhenius plot of log k versus 1/T 
Fig. 4.11. It is found that a plot of In k against 1/T gives a straight line with negative 
slope. This further confirms the first order dependence on the reactants. 
Activation energy (Ea) can be calculated from the slope (-Ea/2.303R) found to 
be 21.1 kJ mol"'. The other activation parameters such as enthalpy, entropy and free 
energy of activation of the reaction product were calculated using Eyring equation: 
log - = log - ^ + 
T h 2.303/? 2.303/? T 
The plot of log k/T versus 1/T Fig. 4.12 was linear with correlation coefficient 
of 0.9841. AH" was evaluated from the slope (-AH'' /2.303R) and AS* from the 
intercept [log (kb/h) + AS /2.303R] of the compiled Eyring plot. The values of AH 
and AS* were found to be 18.5 kJ mof' and -236 J K'' mof' respectively (Table 4.8). 
The Gibbs free energy of activation was determined at 308 K and found to be 88.9 
kJ.mol"' by using, 
AG*= AH*- TAS* 
The moderate values of AH and AS* were both favorable for electron transfer 
processes. The negative value of AS* suggests that the intermediate complex is more 
ordered than the reactants [31]. The observed modest enthalpy of activation and a 
higher rate constant for the slow step indicates that the oxidation presumably occurs 
via an inner-sphere mechanism. This conclusion is supported by earlier observations 
[32]. 
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Fig. 4.14: Spectral changes occurring during the oxidation of Diclofenac sodium 
by permanganate at initial DS concentration of 0.3x10"^ mol.dm"^ and 
KMn04 concentration of 0.5x10'^ mol.dm"^ at 30 °C, the top curve for t 
= 0 min and the bottom for t = 120 min. 
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4.3.6 Spectral Studies 
The absorption spectrum of DS solution in deionised water shows two 
absorption bands peaking at 200 nm and 276 nm shown in Fig. 4.13 while that of 
potassium permanganate solution in the neutral medium exhibits an absorption band 
is peaking at 525 nm. The intensity of the colored product increases with time and 
therefore, a kinetic method was developed for the degradation of DS in drug 
formulation. Reddish-purple coloration is produced in presence of a strong oxidizing 
agent. The changes of spectrum during oxidation of DS with permanganate were 
investigated. The spectral change in the course of the reaction is presented in Fig. 
4.14. As expected, the adsorption intensity in the region 510-600 nm (characteristic 
peak complex for permanganate) decreased gradually as the reaction proceeded. The 
reduction in absorbance with time in a first-order fashion indicates a decreasing 
concentration of Mn04". It is evident from the fig. 4.14, the concentration of Mn04" 
decreases at 526 nm due to Mn (VII). The spectra was measured at different time 
intervals; the top curve for t - Omin and the bottom for t = 120 min respectively. 
In the range of wavelength from 450 to 520 nm, the absorbance also increased with 
time, it is most likely due to the intermediate products produced during DS oxidation. 
Further, research needs to be conducted to identify these intermediates produced from 
the oxidation of DS by permanganate. 
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